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As a result of the advancing development of technologies and applications in 
immunotherapy there is an increasing demand for the discovery of novel therapeutic 
targets. One of the main drivers in this progression is cancer research, which is manifested 
in 2,305 promising immunotherapeutic drugs directed against 378 targets currently in 
preclinical development. Novel applications of immunotherapies in turn require specific 
biomarkers to guide treatment decisions, monitor disease progression and to predict 
patient outcome, further increasing the need for discovery. Typical discovery ventures 
make use of proteomics and transcriptomics approaches that try to provide solutions via 
big data or rely on screening of common peptide or protein libraries against large numbers 
of patient sera. Though effective in some cases, such large scope techniques generally 
do not take into account patient-specific phenotypes and might thereby miss individual 
indications. 
This study presents a novel approach for the selection of potential biomarkers and 
therapeutic targets using fresh untreated tumor tissue and patient antibody repertoires. 
Patient specific cDNA antigen libraries were created from head and neck cancer tissues. 
Autologous antibody repertoires obtained from tumor infiltrating B cells (TIBC) or patient 
sera were used for selection of protein fragments via M13 phage display. 
The technology was tested successfully by selecting mesothelin (MSLN) peptides from 
HCT116 cell line antigen libraries using anti-MSLN antibody SUW57-D11. Panning in 
solution in combination with phage ELISA screening for positive clones was found to be 
the most promising workflow for biomarker and target discovery. High throughput 
applicability of this method was confirmed through successful selections in 96-well format 
and by employing next generation sequencing (NGS) as a single massively parallel 
screening method to replace ELISA. 
Using antibodies from TIBC, protein fragments of known cancer therapy target MMP9 were 
isolated from the antigen libraries, providing proof of principle for the identification of 
potential therapeutic targets. Furthermore, SHTN1 and WWC2 protein fragments were 
enriched in a similar approach. Using patient sera, EEA1 emerged as a protein of interest. 
The presented technology allows target and biomarker discovery based on patient specific 
local and systemic immune responses. This approach yields candidates with an implied 
relevance by basing the selection process on a biological mechanism within the disease 
context. The workflow has the capacity to be advanced towards a target and biomarker 
discovery platform that is applicable not only to cancer, but to diseases that require 
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1.1 Disease background  
1.1.1 Cancer biology 
Cancer is a disease that arises due to a continuous and progressing dysregulation of 
various cellular functions. With few exceptions (for example in childhood cancers) these 
are originally caused by gradual accumulation of DNA damage and mutations that change 
gene regulation and protein expression and function. Over time, a complex interplay of 
different cell types and signalling pathways develops, that enables advancement of the 
disease. The most fundamental change in tumor cells is their ability to proliferate 
indefinitely, achieved through sustained activation of proliferative signalling pathways and 
suppression of growth inhibitors. This constant growth requires a constant supply of 
nutrients which growing tumors establish via induction of angiogenesis, the formation of 
new blood vessels. During further expansion, invasion of surrounding tissues is facilitated 
through manipulation of the extracellular matrix leading to a reduction of local tissue 
cohesion and an increase in cell motility. In later stages some tumor cells undergo 
epithelial-mesenchymal transition allowing complete dissemination from the primary tumor 
and invasion of distant organs via lymphatic and blood vessels1.  
Besides these intrinsic hallmark capabilities, tumors are also influenced by their 
surrounding microenvironment. Next to cells of blood vessels and fibroblasts many cells 
of the immune system, for example macrophages, NK cells and T and B lymphocytes, are 
found within or in the vicinity of solid tumors2. Increased local immune signalling can cause 
tumors to become sites of chronic inflammation leading to further tumor-promoting effects, 
for example release of mutagenic reactive oxygen species1. While T and B cells have been 
shown to elicit tumor specific immune responses, the execution of immune effector 
functions is often impaired, in part due to suppressive signals in the microenvironment3. 
These various genetic and molecular changes coupled with a complex interaction network 
involving different cell types make cancer a highly heterogenous disease the treatment of 
which requires precise diagnostics and highly specific targeted therapies. 
1.1.2 Tumor infiltrating B cells 
Solid tumors are frequently infiltrated by lymphocytes4,5. Tumor-infiltrating lymphocytes 
have strong prognostic potential in many cancers, yet depending on the type of disease 
and the subtype of cells they can have either beneficial or detrimental effects6. In general, 
the effects of infiltrating T cells have been studied to a greater extent than B cells, due to 




do elicit a humoral immune response and that their antibody repertoires may be used to 
target cancer cells7. Furthermore, tertiary lymphoid structures can form in solid cancers, 
which harbour B cells, T cells, dendritic cells and others8. Within these structures immune 
cells are constantly exposed to all sorts of antigens in the surrounding microenvironment. 
They can also allow somatic hypermutation and affinity maturation to take place which are 
important processes for the generation of highly specific antibodies9. This study uses 
antibody repertoires from TIBC from human head and neck cancer tissues for the 
identification of potential novel therapeutic targets. 
1.1.3 Head and neck cancer 
Head and neck cancer is a collective term for all cancers that arise from tissue of the lips, 
oral cavity, throat and upper airways. Incidences are especially high for males with 
511,060 newly diagnosed patients in 2018 compared to 199,117 females10. Primary 
treatment for tumors classified T1-T3 is still surgery in combination with optional 
radiotherapy. Higher stage tumors are treated with primary radiochemotherapy11. Until 
recently, immunotherapies for head and neck cancer, for example with anti-EGFR 
antibody cetuximab, were sparse and mostly regarded as second-line treatments, but their 
development is on the rise and several immune checkpoint inhibitors have been approved, 
especially for recurrent and metastatic disease12. 
1.2 Cancer therapy development 
1.2.1 Immune-oncology and immunotherapy 
Cancer therapy is progressively moving away from unspecific chemotherapy towards 
targeted therapies13. This greatly reduces side effects due to unselective killing of normal 
cells and increases efficacy. Immune-oncology deals with the development and 
investigation of cancer treatments that use the mechanisms of the body’s immune system 
to fight the disease. Despite it being a rapidly growing field of research only 25 protein 
targets can currently be addressed with approved immune-oncologic therapies, with 43 
out 59 agents acting on only 9 targets14,15. There is a great need for the discovery and 
validation of new targets and the according therapies as demonstrated by 3817 agents 
directed against 466 targets currently in preclinical and clinical phase I-III trials15.  
Immunotherapies aim to activate the patients’ immune system. They either target proteins 
or certain types of cells directly by provoking an immune response directed specifically 
against these structures or indirectly by eliciting a general immune response that attacks 
the target structure by coincidence. Cancer immunotherapies can be divided into three 




Vaccination therapy relies on injection of cancer cells, parts of cancer cells, purified 
proteins or protein fragments to cause a direct immune response together with adjuvants 
to boost the reaction. For therapy to be effective, the administered proteins need to be 
either highly overexpressed on cancer cells, a differentiation marker specific to the cancer 
cell type or a mutated neoantigen. Otherwise the vaccination has a high likelihood of failure 
due to self-tolerance mechanisms17. New sophisticated techniques use autologous 
antigen presenting cells (for example dendritic cells) that have been primed with antigen 
ex vivo as vaccination agents. The difficulty of creating effective cancer vaccines is 
demonstrated by the fact that Spileucel-T is the only FDA approved vaccination treatment 
against cancer (hormone-refractory prostate cancer) to date. 
In antibody therapy, recombinant immunoglobulins directed against cancer antigens are 
used to target cancer cells. To reduce side effects, the targeted cancer antigens should 
have similar properties as described for vaccination therapy. Antibodies can cause tumor 
cell killing through immune-mediated mechanisms like complement dependent cytotoxicity 
(CDC), antibody dependent cell mediated cytotoxicity (ADCC) or regulation of T cell 
function. Independent of the immune system antibodies can affect tumors through 
inhibition or activation of signalling pathways resulting for example in induction of 
apoptosis. Antibodies that are rapidly internalized after binding their target can be used to 
deliver cytotoxic agents into the cell18. Bispecific antibodies can be employed to engage 
two targets at once for increased efficacy or to guide immune cells, for example cytotoxic 
T-cells, to the tumor19. Antibody therapeutics may also target the tumor microenvironment 
or stroma. Recently, immune checkpoint inhibitors have shown great promise in fighting 
cancer by releasing immune system blockades20. In addition to these versatile 
applications, the molecular structure of antibodies can be readily modified to improve their 
half-life, solubility and stability which makes them a very flexible tool for immunotherapy. 
Adoptive cell therapy (ACT) makes use of ex vivo expanded and/or modified autologous 
lymphocytes. Tumor infiltrating lymphocytes with the potential to exert anti-tumor activities 
are harvested by biopsies and cultivated to great numbers. After eradication of other 
lymphocytes in the patient’s body through radiation treatment, the expanded cells are 
reinjected to fight the cancer. Via genetic engineering, peripheral blood T cells can be 
modified to express highly antigen specific T cell receptors to recognize cancer cells. 
However, T cell receptor can only recognize short peptides presented via MHC complexes. 
This was overcome by the development of chimeric antigen receptor T (CAR-T) cells.          
T cell receptors are endowed with the antigen binding region of an antibody vastly 




early stage of development but clinical evidence has shown promising efficacy in the 
treatment of cancers21. 
1.2.2 Target discovery 
The development of a drug is preceded by the search for a molecular target that is suitable 
for therapeutic intervention. The target should ideally have a function in disease biology, 
be druggable and not uniformly expressed in the body22. Here, several approaches to 
select protein target candidates for further investigation of their therapeutic potential are 
described.  
Targets can be identified via fundamental research and elucidation of disease biology 
leading to the discovery of novel molecules and proteins that participate in a disease 
mechanism. In a rational approach using literature research and data mining key players 
in disease development can be identified and their potential for therapeutic interventions 
be explored. This process requires great manual effort and has a high risk of failure in the 
following drug development process23. However, the advantage of selecting targets 
through deduction from large amounts of data lies within their advanced molecular 
characterization.  
Target discovery can also be built on previous successful drug discoveries. For example, 
through investigation of members of protein families that have proven to be more readily 
druggable then others24. Similarly, members of effective compound classes that are not 
yet indicated for therapeutic use can be tested in disease models. High throughout 
screenings provide the capacity to test thousands of compounds, for example on 
mammalian cancer cell lines. Effective drug candidates are selected via measurement of 
phenotypical reactions and the molecular target is later identified via target deconvolution 
procedures25. 
Recently, omics technologies (genomics, proteomics, transcriptomics, metabolomics) that 
aim to gather data on all DNA, protein, mRNA or metabolite molecules in a biological 
sample have been employed. These approaches aim to provide a wholistic view of all 
factors that may have implications in disease. However, they are not driven by a specific 
biological mechanism. Factors that are altered in a disease context are identified through 
creation of large databases and comparative analyses26.  
Another target discovery approach relies on exploiting biological mechanisms, for example 
the host immune response. The immune system is a refined biological mechanism for 
targeting biological structures. Patient antibodies can be used to identify novel relevant 
proteins via microarrays27, mass spectrometry28 or phage display29. This approach is 
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especially interesting for identifying targets for immunotherapies which are often guided 
by antibody binding specificities. Using recombinant technologies, the potential 
therapeutic target and corresponding antibodies can be selected in parallel. 
1.2.3 Biomarkers 
Biomarkers can generally be defined as “a biological observation that substitutes for and 
ideally predicts a clinically relevant endpoint or intermediate outcome that is more difficult 
to observe”30. A typical biomarker in cancer would be the expression level of a protein that 
helps to guide precise diagnosis, tumor subtyping or choice of treatment or that can be 
predictive of disease progression. Biomarkers are especially important in cancer 
treatment, since it is a very heterogenous disease that progresses over very long periods 
of time, sometime decades. The ability to make evidence-based treatment decisions as 
early as possible is crucial for the patients’ well-being and survival. 
 
1.3 Phage and ORFeome display 
In general, phage display is used to present proteins or peptides of interest on the surface 
of bacteriophages, for example T7 or M13, to study protein-protein interactions. This is 
achieved by fusing the proteins to one of the coat proteins of the phage. The many different 
phage display systems and applications have been reviewed previously31. The system that 
is the basis for this study accomplishes display by fusion of the desired construct to the 
minor coat protein pIII of bacteriophage M1332. pIII is responsible for binding of M13 to the 
F-pilus of bacteria and thereby crucial for infection. The genetic Information for the   
protein-pIII fusion is encoded on a phagemid vector which can be packaged into the phage 
capsid and be propagated in bacteria, most commonly Escherichia coli.  
The process of selection of protein interaction partners in phage display is called panning 
and consists of four major steps:  
1) immobilization of an interaction partner on a surface 
2) addition of a library of proteins/peptides, displayed on the phage surface, that 
potentially bind the interaction partner 
3) removal of unbound phage 
4) collection of specifically bound phage.  
In a variation, the interaction partner can be applied in solution and captured on a surface, 
e.g. magnetic beads, at the end of the selection process (Figure 1-1). The selected phage 
can be amplified by infection of E. coli and used for further rounds of selection and 




specific antibodies to various antigens33,34 and has also been used to identify epitopes of 
antibodies in a reverse manner35. Effectiveness of polypeptide presentation was improved 
by introduction of the pHORF system, also called ORFeome display. First developed in 
200636, it has so far been used to identify immunogenic peptides and proteins from 
bacteria37–39, metagenomes of gut microbiota40 and tick saliva41. It uses Hyperphage42 to 
enrich open reading frames (ORF) in polypeptide libraries constructed from non-
directionally cloned, randomly fragmented cDNA or genomic DNA. The pIII protein has 
been deleted from the Hyperphage genome so the only source of pIII are intact i.e. in 
frame pIII-fusion constructs which causes their enrichment upon Hyperphage packaging. 
Without ORF enrichment, only 5.55 % of cloned peptide constructs would be in frame with 
pIII and displayed on the phage surface, which greatly reduces efficiency. In this study, 
the ORFeome display technology was improved for the use with human cDNA libraries by 
implementing a more efficient unidirectional cloning process that by design doubles the 
statistical occurrence of in frame constructs prior to Hyperphage packaging.  
 
 
Figure 1-1 – Panning in solution: Schematic overview of the panning procedure. Libraries consisting of 
phage particles that are displaying polypeptides on their surface are mixed with antibodies. Antibodies bind to 
polypeptides according to their specificity. Protein A magnetic beads are used to capture antibodies and 
unbound phage particles are washed away. Bound phage particles are eluted and either amplified for another 




This study aims to develop a technology that can select protein fragments that have the 
potential to become new targets or biomarkers for cancer therapy. Using recombinant 
antibody repertoires from TIBC isolated from fresh head and neck tumor tissue and using 
patient sera, protein fragments are enriched from antigen phage libraries via panning. 
Furthermore, high throughput applicability of the approach is investigated that may allow 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Consumables 
Consumables used in this study are listed in Table 2-1. 
 
Table 2-1: Consumables 
Material Manufacturer 
Amicon Ultra-0.5 ml Centrifugal Filters, 30K Merck KGaA (Darmstadt, DE) 
Cell strainer, 40 µm Fisher Scientific GmbH (Schwerte, 
DE) 
Costar 96 well plate Corning Inc. (Corning, NY, USA) 
Cryo.S Biobankröhrchen, 1000 µl with 2D 
codes 
Greiner-Bio-One (Frickenhausen, DE) 
Cryo.S Biobankröhrchen, 300 µl with 2D 
codes 
Greiner-Bio-One (Frickenhausen, DE) 
Deepwell plate, 24-well, Whatman Uniplate, 
PP, 10 ml 
GE Healthcare (Chicago, IL, USA) 
Deepwell plate, 96-well, Riplate® medio, PP, 
0,5 ml 
Ritter GmbH (Schwabmünchen, DE) 
Disposable Cuvettes, PS, 10 mm Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
Drigalski spatula, sterile VWR International GmbH (Hannover, 
DE) 
Falcon centrifuge tubes, 15 ml Corning Inc. (Corning, NY, USA) 
Falcon centrifuge tubes, 50 ml Corning Inc. (Corning, NY, USA) 
GenePulser Cuvette, 0.1 cm Bio-Rad Laboratories (München, DE) 
Minisart sterile filter, 0.45 μm Sartorius AG (Göttingen, DE) 
MTP 384 well PS-F-bottom Greiner-Bio-One (Frickenhausen, DE) 
MTP 96 well PP F-bottom Greiner-Bio-One (Frickenhausen, DE) 
MTP cover foil, aluminium HJ Bioanalytik GmbH (Erkelenz, DE) 
MTP cover foil, nonwoven HJ Bioanalytik GmbH (Erkelenz, DE) 
Multiply-µStrip Pro8-strip PCR stripes Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
Nitrile gloves, StarGuard STARLAB INTERNATIONAL GmbH 
(Hamburg, DE) 
Nunc Bio Assay Dish (pizza plate) Merck KGaA (Darmstadt, DE) 
PCR plate 96 well, frameless Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
PCR plate 96 well, Semi-Skirted 4titude Ltd (Berlin, DE) 
PCR seal 4titude Ltd (Berlin, DE) 
Petri Dish, 10 cm Greiner-Bio-One (Frickenhausen, DE) 
Pipette tips, 125 μl Integra Biosciences GmbH (Biebertal, 
DE) 
Pipette tips, Combitips advanced: 5 ml, 10 
ml, 25 ml, 50 ml 
Eppendorf AG (Hamburg, DE) 
Pipette tips, filtered: 10 μl, 20 µl, 300 µl, 1000 
µl 
Nerbe Plus GmbH (Winsen/Luhe, DE) 
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Material Manufacturer 
Pipette tips: 10 μl, 20 µl, 200 µl, 1000 µl Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
Pipette tips: 300 μl V96 Tips NS & SF Integra Biosciences GmbH (Biebertal, 
DE) 
Reaction tubes: 1.5 ml, 2 ml Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
Reservoir 300 ml, sterile Integra Biosciences GmbH (Biebertal, 
DE) 
Screw-top tubes, 2ml, PP Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
Serological Pipettes: 2 ml, 5 ml, 10 ml, 25 ml Corning Inc. (Corning, NY, USA) 
SPRI select magnetic beads Beckman Coulter GmbH (Krefeld, DE) 
Strips of 8 Flat Optical Caps 4titude Ltd (Berlin, DE) 
SureBeads™ Protein A Magnetic Beads Bio-Rad Laboratories (München, DE) 
Syringes: 2 ml, 10 ml, 20 ml B.Braun Melsungen AG (Melsungen, 
DE) 
TC-Flask T75, standard Sarstedt AG & Co. KG (Nümbrecht, 
DE) 
 
2.1.2 Technical devices 
Technical devices used in this study are listed in Table 2-2. 
 
Table 2-2: Technical devices 
Device Model Manufacturer 
Agarose Gel Combs 6, 10, 12, 50 wells Peqlab Biotechnologie GmbH 
(Erlangen, DE) 
Autoclave VX-150 Systec GmbH (Linden, DE) 
VX-95 Systec GmbH (Linden, DE) 
Balance Entris 4202l-1S Sartorius AG (Göttingen, DE) 
Genius ME215P Sartorius AG (Göttingen, DE) 
Centrifuge Allegra X-15R  Beckman Coulter GmbH (Krefeld, 
DE) 
5810R Eppendorf AG (Hamburg, DE) 
Sorvall LYNX 4000 
Superspeed  
Thermo Fisher Scientific 
(Dreieich, DE) 
Heraeus Pico 17 
Microcentrifuge  
Thermo Fisher Scientific 
(Dreieich, DE) 
Colony Picker Qpix Molecular Devices, LLC (San 
Jose, CA, USA) 
Counting chamber BLAUBRAND® 
Neubauer, improved 
BRAND GMBH + CO KG 
(Wertheim, DE) 
Electrophoresis chamber 40-0708 Peqlab Biotechnologie GmbH 
(Erlangen, DE) 
40-2314-N Peqlab Biotechnologie GmbH 
(Erlangen, DE) 
Electroporation device MicroPulser™ Bio-Rad Laboratories (München, 
DE) 
Materials and Methods 
10 
 
Device Model Manufacturer 
Freezer -20 °C  Liebherr-International 
Deutschland GmbH (Biberach an 
der Riß, DE) 
Freezer -80 °C Innova U725 Eppendorf AG (Hamburg, DE) 
Fridge 4 °C  Liebherr-International 
Deutschland GmbH (Biberach an 
der Riß, DE) 
Heating plate / magnetic 
stirrer 
MR3001 Heidolph Instruments GmbH & 
Co. KG (Schwabach, DE) 
Imaging System ChemiDoc™ Bio-Rad Laboratories (München, 
DE) 
Incubator IS-2-K Axon Labortechnik GmbH 
(Kaiserslautern, DE) 
Vortemp 56 Labnet International, Inc (Edison, 
NJ, USA) 
ZWYC-290A LABWIT Scientific Pty. Ltd 
(Melbourne, AUS) 
HERAcell Vios 160i Thermo Fisher Scientific 
(Dreieich, DE) 
Heraeus UT 6200 Thermo Fisher Scientific 
(Dreieich, DE) 
Laminar Flow Hood Heraguard ECO Thermo Fisher Scientific 
(Dreieich, DE) 
Safe 2020 Thermo Fisher Scientific 
(Dreieich, DE) 
Light Microscope IX70 Olympus Europa SE & CO. KG 
(Hamburg, DE) 
Magnetic Rack 96S Super Magnet 
Plate 
Alpaqua Engineering, LLC 
(Beverly, MA, USA) 
DynaMag™-2 Thermo Fisher Scientific 
(Dreieich, DE) 
Microplate plate washer EL406 BioTek (Bad Friedrichshall, DE) 
ELx405 BioTek (Bad Friedrichshall, DE) 
Hydro flex Tecan Group AG (Männedorf, 
CHE) 
Microplate reader Sunrise Tecan Group AG (Männedorf, 
CHE) 
Microplate Sealer Quick-Combi Sealer 
Plus 
HJ Bioanalytik GmbH (Erkelenz, 
DE) 
Microplate Stacker BioStack 3 & 4 BioTek (Bad Friedrichshall, DE) 
pH Meter WTW innoLab 
pH7110 
Xylem Analytics Germany Sales 
GmbH & Co. KG (Weilheim, DE) 
Photometer ScanDrop2 Analytik Jena (Jena, DE) 
BioPhotometer Eppendorf AG (Hamburg, DE) 
Pipette Multipette M4 Eppendorf AG (Hamburg, DE) 
Pipette electric 8-
channel 
Voyager Integra Biosciences GmbH 
(Biebertal, DE) 
Pipettes Research Plus: 0,1-
2,5 μl; 
0,5-10 μl; 2-20 μl; 20-
Eppendorf AG (Hamburg, DE) 
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Device Model Manufacturer 
200 μl; 
100-1000 μl 
Pipettes 8-channel Research plus: 0,5-10 
μl; 10-100 μl; 30-300 
μl 
Eppendorf AG (Hamburg, DE) 
Pipettes electric 96-
channel 
Viaflo96 Integra Biosciences GmbH 
(Biebertal, DE) 
Pipettor Acu-Jet Brand (Wertheim, DE) 
Power supply Power Pac HC 200 & 
300 
Bio-Rad Laboratories (München, 
DE) 
Rotator Multi Bio RS-24 SIA Biosan (Riga, LV) 
Sample Rocker Duomax 1030 Heidolph Instruments GmbH & 
Co. KG (Schwabach, DE) 
Sample Roller RS-TR05 Phoenix Instrument (Garbsen, 
DE) 
Shaking plate Unimax 2010 Heidolph Instruments GmbH & 
Co. KG (Schwabach, DE) 
Thermal Cycler T100 Bio-Rad Laboratories (München, 
DE) 
Mastercycler personal Eppendorf AG (Hamburg, DE) 
Thermal Mixer Thermomixer comfort Eppendorf AG (Hamburg, DE) 




Milli-Q UF Plus Merck KGaA (Darmstadt, DE) 
Water bath Shake Temp SW23 Julabo GmbH (Seelbach, DE) 
 
  




Chemicals and reagents used in this study are listed in Table 2-3. 
 
Table 2-3: Chemicals and reagents 
Chemical / Reagent Supplier 
2-propanol Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
3,3',5,5'-Tetramethylbenzidin Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Acetic acid Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Acetone Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Ampicillin sodium salt AppliChem GmbH (Darmstadt, DE) 
Bacto Tryptone BD Biosciences (San Jose, CA, USA) 
Bacto Yeast extract BD Biosciences (San Jose, CA, USA) 
Bovine Serum Albumin PAN-Biotech GmbH (Aidenbach, DE) 
Citric acid Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
D(+)-Glucose monohydrate  Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Dimethyl sulfoxide (DMSO) Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Di-sodium-hydrogenphosphate-di-
hydrat (Na2HPO4 x 2H2O) 
Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
dNTP mix  
Ethanol absolute VWR International GmbH (Hannover, DE) 
Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Glycerol Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Hydrochloric acid, 37 % (HCl) Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Hydrogen Peroxide Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Isopropyl-β-D-thiogalactopyranosid Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Kanamycin sulfate Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
LE-Agarose Biozym Scientific GmbH (Karlsruhe, DE) 
Monopotassium phosphate (KH2PO4) Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Polyethylene Glycol Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Potassium chloride (KCl) Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Potassium citrate Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Recovery Medium Lucigen Corporation (Middleton, WI, USA) 
Sodium Chloride (NaCl) Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Spam-Agar Hellmuth Carroux GmbH & Co. KG 
(Hamburg, DE) 
Sulfuric acid Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
Tetracycline hydrochloride AppliChem GmbH (Darmstadt, DE) 
Tris(hydroxymethyl)aminomethane 
(TRIS) 
Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
TRIzol reagent Thermo Fisher Scientific (Dreieich, DE) 
Tween20 Carl Roth GmbH + Co. KG (Karlsruhe, DE) 
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2.1.4 Bacterial strains, phage and cell lines 
Bacterial strains, phage and mammalian cell lines used in this study are listed in            
Table 2-4. 
 
Table 2-4: Bacterial strains, phage and cell lines 
Strain Genotype/description Application Source 
E. coli SS320 F'[proAB lacIqZ ΔM15 Tn10 
(TetR)] araD139 Δ(ara-
leu)7696 galE15 galK16 
Δ(lac)X74 rpsL (StrR) 









E. coli TG1 [F' traD36 proAB lacIqZ 
ΔM15] supE thi-1 Δ(lac-
proAB) Δ(mcrB-hsdSM)5(rK 









supE44 thi-1 recA1 gyrA96 
relA1 lac [F′ proAB 




Jolla, CA, USA) 
HCT116 Human colorectal 





Hyperphage M13K07DgIII Phage 
production 




Plasmids used in this study are listed in Table 2-5. 
 
Table 2-5: Plasmids 
Plasmid Description Reference 
pHORF3 Phagemid, coding for peptide 
fusions with minor coat protein pIII 
of bacteriophage M13, library 
vector for ORFeome display 
libraries 
Kügler et al. 200843 
pTSD3 Phagemid, coding for peptide 
fusions with minor coat protein pIII 
of bacteriophage M13, library 
vector for unidirectional 




Plasmid, coding for peptide 
fusions with mouse IgG2a Fc part, 
used for production of scFv-Fc 
antibodies in mammalian cell 
culture 
Miethe et al. 201544 




Kits used in this study are listed in Table 2-6. 
 
Table 2-6: Kits 
Kit Application Manufacturer 
NEBNext® Ultra™ II 
Directional RNA Library 
Prep Kit for Illumina® 
cDNA library generation New England Biolabs 
(Frankfurt a. M., DE) 
NEBNext® Poly(A) mRNA 
Magnetic Isolation Module 
mRNA purification New England Biolabs 
(Frankfurt a. M., DE) 
NucleoSpin® Gel and PCR 
Clean-up 
DNA purification Macherey-Nagel GmbH & 
Co. KG (Düren, DE) 
NucleoSpin® Plasmid 
Transfection-grade 
Plasmid extraction Macherey-Nagel GmbH & 
Co. KG (Düren, DE) 
NucleoBond® Xtra Midi Plasmid extraction Macherey-Nagel GmbH & 
Co. KG (Düren, DE) 
Direct-zol RNA Miniprep 
Plus 
total RNA isolation Zymo Research Europe 
GmbH (Freiburg, DE) 
EasySep™ Human B Cell 
Isolation kit  




Antibodies used in this study are listed in Table 2-7. 
 
Table 2-7: Antibodies 
Antibody Description Manufacturer 
11973-MM05T-H Anti-M13 Antibody (HRP) Sino Biological Europe GmbH 
(Eschborn, DE) 
GSM238-B7 anti-MTP64 (M. tuberculosis) 
antibody 
AG Dübel (Braunschweig, 
DE) 
MA1-21315-HRP 6x-His Tag Monoclonal Antibody 
(HIS.H8), HRP 
Thermo Fisher Scientific Inc. 
(Waltham, USA) 
SUW57-D11 anti-mesothelin antibody AG Dübel (Braunschweig, 
DE) 
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2.1.8 Oligonucleotides 
Oligonucleotides were used for the construction of plasmids, as adapters in cDNA library 
generation and as primers for DNA amplification via PCR. All oligonucleotides used in this 
study are listed in Table 2-8. 
 
Table 2-8: Oligonucleotides 
Name ID Sequence 5' → 3' Application 








MHgIII_r  YP11 CTAAAGTTTTGTCGTCTTT
CC  
colony PCR on 
pTSD3 
MHLAacZ-Pro_f  YP125 GGCTCGTATGTTGTGTGG  colony PCR on 
pTSD3 





























*: phosphorothioate bond for increased stability 
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2.1.9 Enzymes, buffers and markers 
The enzymes, commercial buffers and markers used in this study are listed in Table 2-9. 
 
Table 2-9: Enzymes, buffers and markers 
Application Enzyme / Buffer / Marker Manufacturer 
Buffers 
restriction of DNA NEBuffer 3.1 New England Biolabs 
(Frankfurt a. M., DE) 
colony PCR 5x Green GoTaq® 
Reaction Buffer 
Promega GmbH (Mannheim, 
DE) 
restriction of DNA CutSmart Buffer New England Biolabs 
(Frankfurt a. M., DE) 
Endonucleases 
restriction of DNA BamHI HF New England Biolabs 
(Frankfurt a. M., DE) 
digestion of pTSD3 
vector 
BsmbI New England Biolabs 
(Frankfurt a. M., DE) 
restriction of DNA BtgZI New England Biolabs 
(Frankfurt a. M., DE) 
restriction of DNA NheI HF New England Biolabs 
(Frankfurt a. M., DE) 
digestion of pHORF3 
vector 
PmeI New England Biolabs 
(Frankfurt a. M., DE) 
Ligases 
ligation of inserts into 
vector backbones 





Gel loading Dye Purple 6x New England Biolabs 
(Frankfurt a. M., DE) 
agarose gel 
electrophoresis 
GeneRuler 1 kB Plus DNA 
ladder 




HDGreen DNA stain Intas Science Imaging 
Instruments GmbH (Göttingen, 
DE) 
Polymerases 




restricted DNA vectors 
Alkaline Phosphatase, Calf 
Intestinal (CIP) 
New England Biolabs 
(Frankfurt a. M., DE) 
tissue digestion Collagenase G Sekisui Diagnostics LLC 
(Burlington, MA, USA) 
tissue digestion Collagenase H Sekisui Diagnostics LLC 
(Burlington, MA, USA) 
tissue digestion DNase I Sigma-Aldrich (Taufkirchen, 
DE) 
elution of phage Trypsin Sigma-Aldrich (Taufkirchen, 
DE) 
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2.1.10 Media, Supplements and Buffers 
Media, solutions and supplements for mammalian cell culture and cultivation of E. coli 
are listed in Table 2-10, 2-11 and 2-12. Supplements were added under sterile 
conditions. 
 
Table 2-10: Media, solutions and supplements for mammalian cell culture 
Media / Solution Application Manufacturer 
DMSO freezing of HCT116 cells Biochrom GmbH (Berlin, DE) 
FBS superior 
(Fetal Bovine Serum) 
supplement for cultivation of 
HCT116 cells 
Biochrom GmbH (Berlin, DE) 




cultivation of HCT116 cells Biochrom GmbH (Berlin, DE) 
Trypsin/EDTA solution detachment of cells Biochrom GmbH (Berlin, DE) 
 
Table 2-11: Basic media for cultivation of bacteria 
Media Ingredient Composition 
2YT media Bacto Tryptone 1.6 % (w/v) 
Bacto Yeast extract 1.0 % (w/v) 
NaCl 0.5 % (w/v) 
Agar (for solid media) 1.5 % (w/v) 
LB media Bacto Tryptone 1.0 % (w/v) 
Bacto Yeast extract 0.5 % (w/v) 
NaCl 1.0 % (w/v) 
Agar (for solid media) 1.5 % (w/v) 
SOB media Bacto Tryptone 2.0 % (w/v) 
Bacto Yeast extract 0.5 % (w/v) 
NaCl 0.5 % (w/v) 
KCl 0.02 % (w/v) 
SOC media SOB medium 490 ml 
MgCl2 (2 M) 5 ml 
Glucose (2 M) 5 ml 
 
Table 2-12: Supplements for cultivation of bacteria 
Supplement Stock concentration Final Concentration 
Ampicillin (A) 100 mg/ml 100 μg/ml 
Tetracycline (T) 10 mg/ml 20 μg/ml 
Kanamycin (K) 50 mg/ml 100 mM 
Glucose (G) 2 M 100 mM 
IPTG 1 M 50 µM 
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2.1.11 Buffers and solutions 
Non-commercial buffers and solutions are listed below (Table 2-13). If not stated 
otherwise, pH was adjusted using 1 M HCl and 1 M NaOH. 
 
Table 2-13: Non-commercial buffers and solutions 
Buffer/Solution Ingredients Solvent 
10x GA Glucose, 2 M   49.5 % (v/v) 
 
Ampicillin, 100 mg/ml  1 % (v/v) 
2YT medium    49.5 % (v/v) 
Agarose gel Agarose   1.5 % (w/v) TAE buffer 
HDGreen   0.002 % (v/v) 
BSA-PBST BSA    2 % (w/v) PBST 
FC-Buffer FBS superior    2 % (v/v) PBS 
EDTA     1 mM 
Glucose Glucose    2 M Milli-Q water 
Glycerol Glycerol    80 % (v/v) Milli-Q water 
Hydrochloric acid (HCl) HCl     5 M Milli-Q water 
Magnesium Chloride MgCl2     2 M Milli-Q water 
Milli-Q-Tween Tween20    0.05 % (v/v) Milli-Q water 
PBST Tween20    0.05 % (v/v) PBS 
PEG/NaCl Polyethylene glycol   20 % Milli-Q water 
NaCl     2.5 M 
Phage dilution buffer 
(pH 7.5) 
TRIS-HCl (1 M)   1 % (v/v) Milli-Q water 
EDTA     2 mM 
NaCl     20 mM 
Phosphate buffered 
saline (PBS) 
NaCl     0.8 % (w/v) Milli-Q water 
KCl     0.02 % (w/v) 
Na2HPO4 x 2H2O   0.14 % (w/v) 
KH2PO4    0.024 % (w/v) 
TAE buffer TRIS     40 mM Milli-Q water 
EDTA     2 mM 
Acetic Acid    20 mM 
TMBA Potassium citrate   30 mM Milli-Q water 
Citric acid    50 mM 
TMBB Acetone    10 % (v/v)  
Ethanol    89.7 % (v/v) 
Hydrogen peroxide   0.3 % (v/v) 
Tetramethylbenzidine  1 mM 
TMB TMBA     95 % (v/v) 
 
TMBB     5 % (v/v) 
TRIS-HCl (pH 7.5) TRIS     1 M Milli-Q water 
HCl, 5 M    to pH 7.5 
Trypsin Trypsin    10 µg/ml PBS 
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2.1.12 Software 
Software used in this study is listed in Table 2-14. 
 
Table 2-14: Software 
Software Application Reference 
Citavi Citation Swiss Academic Software GmbH 
(Wädenswil, CHE) 
Graph Pad Prism 7 Figures GraphPad Software (San Diego, CA, 
USA) 
Inkscape 0.91 Figures https://inkscape.org/ 
Microsoft office Text and data editing Microsoft Corporation (Redmond, WA, 
USA) 
NCBI BLASTn Identification of cDNA 
insert sequences 
https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Notepad++ Python script editing https://notepad-plus-plus.org/ 
SWISS-MODEL Protein structure 
homology modelling 
Waterhouse et al. 2018) 
Ugene in silico cloning, 
sequence analysis, 
sequence alignment 
UniPro, Novosibirsk, RU 
Vortex Data analysis, figures CM Labs Simulations (Montreal, CAN) 
 
  





Experimental plans and patient information material were approved by the ethics 
committee of the TU Braunschweig. Patients were briefed on the scope and aims of this 
study by their physician prior to giving their consent. None of the conducted procedures 
and the collected data allow conclusions about the patient’s identity. 
2.2.2 Tissue handling 
2.2.2.1 Samples 
Fresh head and neck tumor dissections in 0.9 % saline solution were obtained from the 
Hals-Nasen-Ohren-Klinik of the Städtisches Klinikum Braunschweig. Tissues were 
processed in the lab no later than 2 h after dissection. Samples were collected without 
special regards to age and sex of the patients or stage of disease. 
2.2.2.2 Creation of a single cell suspension 
First, tissues were manually minced with small surgical scissors. Then, tissues were 
subjected to an enzymatic digest with 10 U Collagenase H, 3.4 U Collagenase G and       
0.3 U DNase I for 1 h at 37 °C in FC buffer. Afterwards tissues pieces were pushed through 
a 40 µm cell strainer (Fisher Scientific GmbH, Schwerte, DE) with a syringe plunger and 
the strainer was flushed with 2 ml FC buffer.  
2.2.2.3 B cell separation and storage 
B cells were isolated from single cell suspensions (see section 2.2.2.2) using the 
EasySep™ Human B Cell Isolation kit (Stemcell Technologies, Vancouver, CAN), which 
works by CD19 negative selection, according to manufacturer’s instructions. The non-
selected fractions of cells, containing all CD19 negative cells, were also collected. CD19 
B cells and pooled non-B cell fractions were spun down at 300 xg for 5 min, supernatants 
were discarded and 1 ml of TRIzol reagent was added per up to 107 cells. Samples were 
stored at -80 °C up to 12 months. B cells were used to generate recombinant antibody 
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2.2.3 Molecular biological methods 
2.2.3.1 DNA extraction 
Plasmid DNA from E. coli cultures was isolated using the NucleoSpin® Plasmid or the 
NucleoBond® Xtra Midi kit (Macherey-Nagel GmbH & Co. KG, Düren, DE), according to 
manufacturer’s instructions. 
2.2.3.2 RNA extraction 
Whole RNA from tissue and cell line samples dissolved in TRIzol reagent was extracted 
using the Direct-zol RNA Miniprep Plus kit (Zymo Research Europe GmbH, Freiburg, DE), 
according to manufacturer’s instructions.  
2.2.3.3 Agarose gel electrophoresis 
DNA vectors, digested DNA vectors and fragments and PCR amplification products were 
analysed and purified on agarose gels. 1.5 % (w/v) agarose gels containing 1:50.000 (v/v) 
HDGreen DNA stain (Intas Science Imaging Instruments GmbH, Göttingen, DE) were run 
in TAE buffer at 130 V for 25-40 min. As a marker GeneRuler 1 kB Plus DNA Ladder Mix 
(Thermo Fisher Scientific, Dreieich, DE) was used. Gels were imaged on a ChemiDoc 
imaging system (Bio-Rad Laboratories, München, DE). For purification of fragments, gel 
pieces were cut out with a ceramic scalpel. 
2.2.3.4 DNA purification 
Digested DNA vectors, DNA fragments and PCR products were purified directly from the 
reaction mix or after separation on an agarose gel using the PCR clean-up kit (Macherey-
Nagel GmbH & Co. KG, Düren, DE), according to manufacturer’s instructions. 
2.2.3.5 Colony PCR 
Colony PCR was performed after library cloning to estimate the insert rate i.e. percentage 
of plasmids that carry an insert or during cloning to select positive clones for sequence 
confirmation. For the pTSD3 vector, primers YH11 and YH125 were used. Colony PCR 
reactions were setup as follows (Table 2-15).  
Table 2-15: Composition of colony PCR reaction 
Component Final Concentration 
5x Green GoTaq reaction buffer 1x 
10 mM dNTP mix 200 µM 
forward primer 500 nM 
reverse primer 500 nM 
GoTaq2 DNA Polymerase 0.25 U/µl 
Milli-Q H2O Up to 10 µl 
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The thermal cycler was set to the following program (Table 2-16).  
Table 2-16: Thermal cycler program for colony PCR 
Phase Temperature Time 
Initial 95 °C 2 min 
Denaturation 95 °C 30 s 
Annealing 55 °C 20 s 
Elongation 72 °C 30 s 
Final Elongation 72 °C 5 min 
 
2.2.3.6 DNA Sanger Sequencing 
To confirm successful cloning and to identify antigen inserts selected during panning, DNA 
sequencing was performed. Bacterial cultures or plasmid DNA from the appropriate single 
bacterial clones were prepared and sent to Microsynth Seqlab GmbH in Göttingen for 
Sanger sequencing. 
2.2.4 Cloning 
2.2.4.1 Construction of pTSD3 
The pTSD3 vector was constructed form pHORF3. pHORF3 vector restriction digest was 
composed as described in Table 2-17.  







The reaction was carried out at 37 °C for 1 h. 1 µl of CIP was added, followed by brief 
vortexing and incubation at 37 °C for 1 h. The reaction was inactivated by incubation at  
80 °C for 20 min. Plasmid digestion was checked and purified by agarose gel 
electrophoresis. To this end, the whole volume was mixed with the appropriate amount of 
6x Purple Gel Loading Dye (New England Biolabs, Frankfurt a. M., DE). The band 
corresponding to the digested vector was cut from the gel under UV light and plasmid DNA 
was extracted.  
Oligonucleotides YH432 and YH433 were mixed in a molar ratio of 1:1 and diluted in      
Milli-Q H2O for a final concentration of 100 nM. The sample was heated to 90 °C for 5 min 
and slowly cooled to room temperature to allow annealing of the complementary strands. 
Ligation of the oligonucleotide fragment into the pHORF3 backbone was carried out at     
Reagent amount 
pHORF3 plasmid DNA 5 µg 
CutSmart buffer 2 µl 
NheI HF 1 µl 
BamHI HF 1 µl 
Milli-Q H2O Up to 20 µl 
30 cycles 
 
Materials and Methods 
23 
16 °C overnight followed by heat inactivation at 65 °C for 10 min. Ligation reaction was 
composed as described in Table 2-18. 
Table 2-18: Composition of the ligation reaction for pTSD3 
construction 
Reagent amount 
annealed oligonucleotides (100 nM) 0.6 µl 
T4 DNA ligase buffer (10x) 2 µl 
digested pHORF3 vector backbone 
(BamHI HF & NheI HF) 
50 ng 
T4 DNA ligase 1 µl 
Milli-Q H2O Up to 20 µl 
 
10 µl of ligation reaction were added to 25 µl of chemically competent E. coli XL1 blue 
MRF’ bacteria and incubated on ice for 20 min. Heat shock was applied at 42 °C for 1 min. 
165 µl of pre-warmed SOC medium were added and the culture was incubated at 37 °C 
and 650 rpm for 1 h. The complete volume was spread on 2YT-GA agar plates which were 
incubated at 37 °C overnight. 
2.2.4.2 cDNA fragment generation for antigen libraries 
Using 1 µg freshly isolated RNA (see section 2.2.3.2) as starting material, the NEBNext® 
Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ipswich, MA, USA) was 
used in combination with the NEBNext® Ultra™ II Directional RNA Library Prep Kit for 
Illumina® (New England Biolabs, Ipswich, MA, USA) to generate strand-specific cDNA 
libraries, according to manufacturer’s instructions. As suggested, SPRIselect (Beckman 
Coulter GmbH, Krefeld, DE) magnetic beads were used for all nucleotide purification 
steps. The following changes were made to the protocol: 
1. For adapter ligation a newly designed oligonucleotide (YH558) was used to 
introduce BtgZI restriction sites on both sides of the insert. 
2. To test the creation of libraries with different insert sizes (see section 3.2.1), RNA 
fragmentation time was adjusted to 7 min or 5 min instead of 15 min. 
3. For PCR Enrichment of Adaptor ligated DNA, primers YH559 and YH560 were 
used. PCR was run for 15 cycles. 
The resulting amplified cDNA fragments were either stored at -20 °C for a maximum of   
24 h or immediately used for cloning into pTSD3 vector. 
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2.2.4.3 Cloning of tumor tissue cDNA fragments into pTSD3 vector 
pTSD3 vector was digested in larger batches and used for several library cloning 
experiments. The restriction digest was composed as described in Table 2-19.  





The reaction was carried out at 55 °C for 2 h. 1 µl of CIP was added, followed by brief 
vortexing and incubation at 37 °C for 1 h. BsmBI was inactivated by incubation at 80 °C 
for 20 min. Plasmid digestion was checked and purified by agarose gel electrophoresis. 
The whole volume was mixed with the appropriate amount of 6x Purple Gel Loading Dye 
(New England Biolabs, Frankfurt a. M., DE) and separated on a 1.5 % agarose gel running 
at 130 V in NE buffer for 35 min. The band corresponding to the digested vector was cut 
from the gel with a scalpel under UV light and plasmid DNA was extracted.  
Library cDNA fragments were digested at 60 °C for 2 h with the reaction composition 
described in Table 2-20. 
Table 2-20: Composition of cDNA fragment restriction 
digest reaction 
Reagent amount 
amplified cDNA fragments 20 µl 
CutSmart buffer 5 µl 
BtgZI 1 µl 
Milli-Q H2O to 50 µl 
 
Digested fragments were purified using SPRIselect beads (Beckman Coulter GmbH, 
Krefeld, DE) according to manufacturer’s instructions by applying 90 µl of beads. Ligation 
of cDNA fragments into pTSD3 vector was carried out at 16 °C for 5 h followed by heat 
inactivation at 65 °C for 10 min. The reaction was composed as described in Table 2-21. 
Table 2-21: Composition of cDNA fragment ligation 
reaction 
Reagent amount 
purified cDNA fragments 20 µl 
T4 DNA ligase buffer (10x) 10 µl 
digested pTSD3 vector 
backbone (BsmBI) 
100 ng 
T4 DNA ligase 1 µl 
Milli-Q H2O to 100 µl 
Reagent amount 
pTSD3 plasmid DNA 25 µg 
NEBuffer 3.1 10 µl 
BsmBI 2 µl 
Milli-Q H2O Up to 100 µl 
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Prior to electroporation, ligation reactions were subjected to desalting using Amicon Ultra-
0.5 Centrifugal Filter Unit with a 30 kDa cut-off (Merck KGaA, Darmstadt, DE) to remove 
unwanted salts and facilitate successful transformation. 100 µl of ligation reaction were 
added to the column. The volume was brought to 400 µl by adding Milli-Q H2O and the 
column was spun at 16.000 xg for 10 min. This was repeated two more times for a total of 
three centrifugations. Concentrated, desalted, ligated DNA was eluted from the column by 
placing it upside down in a new collection tube and spinning it at 2.000 xg for 10 seconds. 
2.2.4.4 Transformation of electrocompetent E. coli 
SS320 electrocompetent E. coli (Lucigen Corporation, Middleton, WI, USA) were used for 
electroporation. 25 µl of cells were mixed with 10 µl of ligation reaction. The mixture was 
placed into pre-chilled 0.1 cm GenePulser cuvettes (Bio-Rad Laboratories, München, DE) 
and pulsed with 1.8 kV on a BioPulser system (Bio-Rad Laboratories, München, DE). 1 ml 
Recovery medium (Lucigen Corporation, Middleton, WI, USA) pre-warmed to 37 °C were 
added immediately and the cells were transferred to a new tube. Bacteria were incubated 
at 650 rpm and 37 °C for 1 h in a thermal mixer (Thermo Fisher Scientific, Dreieich, DE). 
10 µl of electroporated cells were taken for estimation of transformation efficiency. The 
remaining bacterial culture was spread on 2YT-GAT pizza plates and grown overnight at 
37 °C. 35 ml of 2YT medium were added and plates were rocked on a sample rocker for 
30 min. Bacteria were scraped off with an L-spatula. The liquid culture was collected and 
used to create 12 glycerol stocks. From the remaining bacteria, plasmid DNA was isolated. 
Insert rates were estimated by performing colony PCR on 24 clones from the 2YT-GA 
plates used for estimation of transformation efficiency. 
2.2.4.5 Estimation of transformation efficiency 
In 2YT medium, electroporated cells were diluted and spread on 2YT-GA agar plates for 
final dilutions of 10-4 and 10-6. Colonies were grown overnight at 37 °C. Colonies were 
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2.2.5 Bacterial cultivation techniques 
2.2.5.1 Sterilization 
Prior to use, all media and supplements were sterilized in an autoclave at 121 °C and          
1 bar for 20 min. Temperature sensitive liquids were passed through a 0.2 µm filter. 
2.2.5.2 Bacterial cultures 
Bacteria cultures on agar plates were incubated at 37 °C in a standing incubator. Liquid 
cultures were incubated 37 °C in flasks or microtiter plates in shaking incubators at           
250 rpm and 800 rpm respectively. 
2.2.5.3 Storage of bacterial cultures (glycerol stocks) 
For long-term storage, bacterial cultures were supplemented with 80 % glycerol stock 
solution to achieve a final concentration of 20 %, mixed well and stored at -80 °C. 
2.2.5.4 XL1 and TG1 cultures for infection 
30 ml 2YT medium were inoculated from 1 ml TG1 glycerol stocks with an OD600 of about 
0.7. 30 ml 2YT-T medium were inoculated from 1 ml XL1 Blue MRF’ glycerol stocks with 
an OD600 of about 0.7. Cultures were grown at 37 °C and 250 rpm until an OD600 of            
0.4-0.5. If not otherwise specified, infection was carried out at 37 °C for 30 min with and 
then 30 min without shaking at 250 rpm or 300 rpm in a ZWYC-290A incubator (LABWIT 
Scientific Pty. Ltd, Melbourne, AUS) (for flasks and 96-well MTPs, respectively) or 500 rpm 
or 800 rpm in a Vortemp56 incubator (Labnet International, Inc, Edison, NJ, USA) (for      
24-deepwell plates and 96-well MTPs, respectively). 
2.2.5.5 Production of monoclonal peptide-pIII fusion proteins for screening ELISA 
Randomly chosen bacterial clones that were selected during panning were used to 
inoculate 150 µl of 2YT-AT-IPTG medium in 96-well microtiter plates. Cultures were grown 
at 300 rpm and 30 °C overnight.  
2.2.6 Phage handling 
2.2.6.1 Hyperphage packaging for ORF enrichment 
To present the peptides that are contained in the libraries on the surface of phage particles, 
the libraries were packaged using Hyperphage42. Library packaging was performed as 
described by Fühner et al.35 with minor changes to the protocol. Initial inoculation was 
done with 1 ml library glycerol stock preparation in 400 ml 2YT-GAT medium in 1 l baffled 
flasks (step 4. under section 3.3). The following phage particle production was carried out 
in 600 ml 2YT-AK medium in 2 l non-baffled flasks at 25 °C (step 7. under section 3.3). 
Phage particle pellets were taken up in phage dilution buffer instead of PBS. 
 
Materials and Methods 
27 
2.2.6.2 Titration 
Dilutions for titration were done using PBS. Titers of Hyperphage packaged libraries and 
amplified and eluted phage particle solutions were determined as described before45.  
2.2.6.3 Panning 
2.2.6.3.1 Surface panning in MTP 
Antigen panning in MTP format was performed as described by Fühner et al.35 with the 
following changes to the protocol. Instead of Panning Block solution, 2 % BSA PBST were 
used. Preincubation with a negative control antibody was omitted. XL1 Blue MRF’ and 
TG1 E. coli cultures were inoculated from glycerol stocks on the day of use, not from 
overnight cultures. A second and third panning round were performed. For amplification of 
phage particles, the whole elution volume from the previous round was used for infection 
and Hyperphage was used for polyvalent display (step 3 and 4 under section 3.7). The 
third panning round was stopped after elution of phage particles. 
2.2.6.3.2 Panning in solution 
All 1.5 ml reaction tubes used for panning were blocked with 2 % BSA-PBST for at least  
1 h prior to use. Blocking solution was removed by pipetting. 300 µl 2 % BSA-PBST were 
placed in a tube. An equivalent of at least 50x the estimated diversity of the library of 
peptide presenting Hyperphage particles (in most cases 5 x 108) was added, followed by 
addition of 200 ng of the desired antibody for selection. For patient serum, 50 µl of a 1:1000 
dilution in PBS were added. The panning reaction was incubated while rotating at 15 rpm 
on a Multi Bio RS-24 rotator (SIA Biosan, Riga, LV) for 2 h. Antibodies were captured from 
the panning solution using SureBeads™ Protein A Magnetic Beads (Bio-Rad Laboratories, 
München, DE). 15 µl of beads for each panning reaction were prepared according to 
manufacturer’s instructions and added to the mixture. After 10 min incubation while 
rotating at 15 rpm, tubes were placed on a DynaMag™-2 magnetic rack (Thermo Fisher 
Scientific, Dreieich, DE) and the supernatant was discarded. Beads were washed five 
times with 800 µl PBST with 3 s vortexing and 30 s magnetization in between. After the 
second and third panning round, washing steps were increased to 10 and 15 times, 
respectively. Finally, beads were resuspended in 200 µl 10 µg/ml Trypsin solution and 
phage particles were eluted at 37 °C for 30 min. The tube was placed on the magnetic 
rack and the eluate was removed.  
Amplification of phage particles with Hyperphage was carried out as described before35 
using the whole 200 µl of eluted phage particles. 
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2.2.6.3.3 Panning in 96-well plate 
Conducting panning in a 96-well plate follows the same principles as described before 
(see section 2.2.6.3.2) with some adaptations due to the format. All used wells of a              
V-bottom 96-deepwell plate (Ritter GmbH, Schwabmünchen, DE) were blocked with       
700 µl 2 % BSA PBST. Total volume of the panning mixture was reduced to 500 µl, using 
only 250 µl 2 % BSA PBST. Panning and bead capturing process were incubated in a 
Vortemp56 incubator Vortemp56 incubator (Labnet International, Inc, Edison, NJ, USA) at 
25 °C and 650 rpm. Washing steps were performed using the mixing option of a                  
96-channel electric Viaflo96 pipette (INTEGRA Biosciences GmbH, Biebertal) with          
300 µl PBST and a speed setting of 8 out of 10 for 3 cycles. A 96S Super Magnet Plate 
(Alpaqua Engineering LLC, Beverly, MA, USA) was used for magnetizations. The elution 
reaction was also incubated in a Vortemp incubator at 37 °C and 650 rpm. 
2.2.6.4 Production of monoclonal phage particles for screening ELISA 
Randomly chosen bacterial clones that were selected during panning were used to 
inoculate 150 µl of 2YT-GAT medium in 96-well microtiter plates. Cultures were grown at 
300 rpm and 37 °C for 2 h. 5 x 108 Hyperphage particles were added and infection was 
carried out at 37 °C for 30 min without and then 30 min with shaking. Plates were then 
spun at 3220 xg for 10 min and supernatants were discarded. 200 µl of 2YT-AK medium 
were added and plates were incubated at 30 °C and 300 rpm overnight. 
 
2.2.7 Immunological assays 
2.2.7.1 Screening ELISA with monoclonal phage 
Sample antibody mixture, either 20 ng oligoclonal scFv-Fc or 30 µl of patient serum diluted 
1:4000 in PBS, were coated in 30 µl of PBS at 4 °C overnight. Antibody solutions were 
knocked out of the wells and wells were then blocked with 1 % BSA PBST for 1 h. 30 µl of 
phage production supernatant were added and incubated for 1 h. 30 µl anti-M13 antibody 
coupled to HRP (final concentration: 55 ng/µl) in PBS were added and incubated for 1 h. 
Between incubation steps wells were washed three times with Milli-Q PBST. Binding was 
visualised by addition of 30 µl 3,3′,5,5′-tetramethylbenzidine substrate and the reaction 
was stopped by adding 30 µl 1 N sulfuric acid. Using a Sunrise microtiter plate reader 
(Tecan Group AG, Männedorf, CHE), absorbance at 450 nm and scattered light at 620 nm 
were measured. For signal evaluation the scattered light intensity was subtracted from the 
absorbance value. 
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2.2.7.2 Screening ELISA with peptide-pIII fusions 
Peptide-pIII fusion ELISA was, in principle, performed as described for phage particle 
ELISA. Phage production supernatants were replaced by supernatants of peptide-pIII 
fusion productions. For detection, 30 µl anti-His-tag antibody coupled to HRP (final 
concentration: 62.5 ng/µl) in PBS was used. 
 
2.2.8 Next generation sequencing 
2.2.8.1 sequencing library preparation 
30 ml XL1 Blue MRF’ E. coli cultures were infected with phage packaged unselected library 
with an 50x excess of library diversity. 4 ml XL1 Blue MRF’ cultures were infected with 
phage particles that were amplified or eluted during panning, using 1 x 108 amplified phage 
particles or 100 – 200 µl of the elution solution. Bacteria were pelleted by centrifugation at 
3220 xg, supernatants were discarded, and pellets were taken up in the same volume   
2YT-GA medium. Cultures were grown at 37 °C and 250 rpm overnight. Plasmid DNA was 
isolated and sent to the EMD Serono Research & Development Institute for NGS analysis. 
Sequencing libraries were kindly prepared by Thomas Clarke using either the MiSeq 
Reagent Kit v3 (150 cycles) or the NextSeq 500/550 Mid Output Kit v2.5 (150 cycles) from 
Illumina according to manufacturer’s instructions. Sequences were read using an Illumina 
MiSeq or NextSeq500 system running for 75 or 150 cycles, respectively. 
 
2.2.9 Computational methods 
2.2.9.1 NGS sequence analysis 
After base calling and quality scoring sequencing reads were passed through general 
quality control eliminating low quality reads from the data using the provided software on 
the Illumina BaseSpace platform. From sequences generated thereby, primer and pTSD3 
vector sequences were trimmed away. Using the pseudoaligner kallisto, reads were 
aligned to genes and counted. For the estimation of unique sequences within the libraries, 
a custom python script was created. The script used .fastq files with sequences that 
passed quality control as input and trimmed away primer and pTSD3 vector sequences. A 
sequence was accepted as unique when it differed in length or sequence by at least 1, 
compared to all other sequences. Only forward reads were used for the analysis of unique 
sequences. 
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2.2.9.2 Sequence alignments 
Sequence alignments were performed using the ClustalW algorithm embedded in Ugene 
(UniPro, Novosibirsk, RU) with gap opening penalty set to 70 and gap extension penalty 
set to 10. 
2.2.9.3 BLASTn analysis 
The identity of insert sequences selected during panning and screening is analysed by an 
NCBI BLASTn search against the human genomic and transcript reference sequences. 
Those sequences that have 100 % query cover and share at least 98 % identity with the 
reference are considered matches. 
 
2.2.10 Cell biological methods 
All work regarding mammalian cell culture was kindly performed by Melanie Philippi and 
Marie Kastull. 
2.2.10.1 Cultivation of mammalian cells 
HCT116 cells were cultivated according to ATCC guidelines, as stated on their website 
and used as a source of total RNA for antigen library generation. 
2.2.10.2 Harvesting of HCT116 cells for RNA extraction 
Supernatants were discarded. Cells were detached from the dish surface by applying 2 ml 
Trypsin/EDTA solution and incubation at 37 °C for 5-10 min. Cells were taken up in 10 ml 
McCoy's 5a Medium and counted in a Neubauer chamber (BRAND GMBH + CO KG, 
Wertheim, DE) under a IX70 light microscope (Olympus Europa SE & CO. KG, Hamburg, 
DE). 107 cells were pelleted by centrifugation at 300 xg for 5 min, supernatants were 




The patient samples that were procured for this study received anonymous descriptors 
consisting of the word “Yuhan” (for Yumab – Head and Neck Cancer) and a number, for 
example Yuhan007. Throughout this work patients or patient samples will only be referred 
to via these descriptors. 
The following descriptions of experiments and results sometimes refer to oligoclonal 
recombinant antibody mixtures (kindly provided by Melanie Philippi). These were not 
individually composed following a rationale. They were created using scFv antibody 
libraries derived from tumor infiltrating B cells (TIBC) that were isolated from patient tissue. 
The scFv fragments were transferred into the scFv-Fc expression vector                   
pCSE2.6-mIgG2a-Fc-XP44 via mass cloning and plasmid DNA preparations thereof were 
used to transfect HEK293-6E cells for production. Therefore, the exact content and 
stoichiometry of these mixtures are unknown. However, they represent the local antibody 
repertoire from within and around the tumor tissue.  
 
3.1 Construction of the pTSD3 ORFeome display system 
The previously described ORFeome display methods relied on DNA fragmentation by 
sonication and blunt end cloning into the phagemid vector pHORF343. In first experiments 
using cDNA from cultured mammalian cells, sonication and blunt end cloning of cDNA 
fragments were not efficient and resulted in insert rates not exceeding 15 %. To improve 
cloning efficiency, a sticky end and unidirectional, coding stand-specific cloning procedure 
was tested. This strategy was also expected to double the number of inserts that are 
ligated with correct orientation to the gIII fragment. For this purpose, the new vector pTSD3 
was constructed from the pHORF3 plasmid (Figure 3-1) by replacing the PmeI cloning site 
of pHORF3 with a stuffer fragment containing two asymmetric BsmBI type IIS restriction 
sites. This approach allows insertion of random cDNA fragments that have been ligated to 
the YH558 adapter. This adapter allows digestion with the restriction enzyme BtgzI to 
generate asymmetric, complementary overhangs for unidirectional cloning downstream of 
the 5’ PelB signal peptide and upstream of the 3’ His-tag and gIII sequence. By employing 







Figure 3-1 – pHORF3 and pTSD3: Schematic vector map of pHORF3 and pTSD3 showing the changed 
cloning site. RBS: ribosome binding site; PelB: leader peptide; amber: amber stop codon (TAG); gIII: gene 
coding for phage pIII protein; ochre: ochre stop codon (TAA). (adapted from Kügler et al.43) 
 
3.2 Antigen library analysis 
3.2.1 Insert size for antigen display was limited to about 350 bp 
Selection of peptides or protein fragments from antigen libraries against their 
corresponding antibodies (or antisera) greatly depends on their folding. While some 
antibodies bind short linear peptides, a significant portion requires the formation of a 
secondary or tertiary structure for correct antigen recognition46. Such antigens may only 
be identified if these conformations can be represented on the phage surface. The display 
of mammalian antigens on phage requires their secretory expression as pIII fusion proteins 
in the heterologous E. coli system. Bacteria lack the complex protein folding machinery of 
mammals and express larger proteins with low efficiency. However, many proteins are 
composed of several different protein domains which can form a correct tertiary structure 
despite representing only a fraction of the complete polypeptide chain of the protein. Such 
protein domains range in length from about 30 aa to 500 aa with the majority of domains 
having a size of less than 200 aa47, which corresponds to 600 bases of coding mRNA 
sequence. Chains of less than 100 aa (300 coding bases) are mostly unfavourable for 
folding due to higher free energies of the unfolded states48. In order to increase the chance 
of full protein domains being present in the libraries, three HCT116 cell line libraries with 
intended average fragment sizes of 500, 350 and 200 bp were constructed (termed S1, 
S2 and S4) by adjusting the RNA fragmentation time in the library generation procedure. 
From the three resulting libraries, single clones were selected before and after packaging 
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with Hyperphage, sent for Sanger sequencing and analysed for their insert length. 
Reducing RNA fragmentation by lowering incubation time from the standard 15 min 
approach (S4) that aims for an average insert size of 200 bp to 7 min (S2) did not yield a 
noticeably different insert size distribution (Figure 3-2). Decreasing fragmentation time to 
5 min yielded a library with a much broader insert size distribution, with 41.7 % of inserts 
exhibiting a length greater than 350 bp in library S1 compared to 13.7 % in library S4.  
Single inserts even reached lengths of around 850 bp. However, after Hyperphage 
packaging only 3.17 % of inserts with a length greater than 350 bp are present, showing 
that the packaging process in E. coli selects against larger pIII-fusion peptides. For this 
reason, all following libraries were created using the standard 15 min fragmentation 
protocol in order to achieve maximum diversity in the lower size cDNA fragments and to 
reduce the risk of losing antigen fragments that would drop out during Hyperphage 
packaging. 
 
Figure 3-2 – Insert size distribution: Histogram of cDNA insert size distributions for HCT116 libraries S1, S2 
and S4 before and after packaging with Hyperphage. Libraries were generated with different RNA 






3.2.2 In frame ORF inserts are highly enriched after Hyperphage packaging 
Depending on their length, randomly fragmented and unidirectionally cloned cDNA inserts 
can be present in one of three possible reading frames. In pTSD3, inserts that have a 
length divisible by three are in frame with the gIII sequence. The number of in frame 
constructs should greatly improve through packaging with Hyperphage, because only 
inserts without stop codon and without a reading frame shift are assumed to gain infectivity. 
To check ORF enrichment, single clones from the HCT116 S1, S2 and S4 libraries (see 
section 2.2.1) were analysed by Sanger sequencing before and for S1 and S4 also after 
packaging. Before packaging, 32.2 % of inserts are in frame, which is in accordance with 
the expected theoretical value of 33.3 % (Figure 3-3). After Hyperphage packaging the 
amount of in frame sequences increases to 81.7 %, demonstrating effective ORF 
enrichment. While roughly 11 % percent of sequences should contain ORFs that encode 
peptides aligning to human protein sequences prior to packaging, this is only the case for 
2 % (3 out of 146 sequences). All other in frame sequences contained stop codons. 
 
Figure 3-3 – ORF enrichment: A total of 228 individual randomly picked clones from different HCT116 cell 
line pTSD3 libraries were sequenced before and after packaging with Hyperphage. Percentage of insert 
sequences that are in frame with the gIII sequence and percentage of sequences that match ORFs of proteins 






3.2.3 Next generation sequencing analysis of ORFeome libraries 
Antigen display libraries were created from head and neck cancer tissue as well as from 
cancer cell lines. To get a deeper insight into the contents of these libraries, the Yuhan007, 
Yuhan008 and Yuhan011 patient libraries and the HCT116 S4 cell line library were 
analysed using next generation sequencing (NGS). To this end, plasmid DNA was isolated 
from E. coli XL1 blue MRF’ bacteria after infection with phage packaged antigen libraries 
and used for NGS sequence analysis. All libraries were analysed in an Illumina MiSeq 
sequencing run, Yuhan007 and Yuhan008 were also part of a larger second sequencing 
run using the Illumina NextSeq platform. 
The number of genes that are represented in the libraries with at least low coverage ranges 
from 3,541 to 7,169 (Table 3-1). Judging by the raw reads from the NextSeq run, the 
highest sequence diversity was reached at 3.7 x 106 unique sequences in 17,041,751 
reads, after excluding empty vectors and reads containing incorrect vector backbone 
sequences. Sequences were termed unique when they differed at least by one base in 
length or sequence. 
Aligning sequences that mapped to a single gene to the reference genome in the UCSC 
genome browser shows, that only exon sequences were present in these libraries         
(Figure 3-4 A and B). 
The generated antigen libraries roughly covered up to one third of the human 
transcriptome. The exclusive presence of exon sequences demonstrates that the 
transcriptome library design was applicable for phage display libraries made from human 
RNA. 
 
Table 3-1: Gene diversity of cDNA libraries; number of genes that are represented 
in the antigen libraries with a read depth of more than 10, 100 or 1000 reads as 
determined by a MiSeq NGS run 
 Yuhan007 Yuhan008 Yuhan011 HCT116 S4 
>10 reads 7169 3541 5760 6226 
>100 reads 1381 408 717 822 








Figure 3-4 – Exon coverage: Per base read depth of Beta-actin (ACTB) (A) and Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) (B) sequences represented in four antigen libraries aligned to gene sequences 








3.3 Technology validation 
3.3.1 Binding peptides can be selected from antigen libraries using scFv-
Fc antibodies 
The aim of this work was to identify new polypeptide antigens that are bound by antibodies 
derived from the same patient tumor sample. In order to establish the procedures for the 
identification of antigenic polypeptides from the libraries using antibodies, phage display 
panning of the HCT116 S4 library (see section 2.2.1) was performed against the 
monoclonal human anti-mesothelin (MSLN) antibody SuW57-D11. From the amplified 
phage particles after the second panning round, 92 clones were analysed in form of 
secreted antigen-pIII fusion proteins by ELISA. Five out of 6 clones with signal to noise 
ratios greater than 4 and 5 compared to isotype and BSA control, respectively, were sent 
for Sanger sequencing (Figure 3-5). All five antigen clones contained MSLN sequences 
according to NCBI BLASTn, demonstrating that specifically bound protein fragments or 
peptides can be isolated from the antigen libraries via antigen phage display. The selected 
inserts were 216 or 219 bp long and identical in sequence except for three additional bases 
of the longer insert.  
 
Figure 3-5 – Peptide screening ELISA for MSLN panning in MTP format: Peptides selected by MTP 
panning were tested for their binding to anti-mesothelin antibody SuW57-D11 scFv-mouse-Fc in ELISA as 
antigen-pIII fusion proteins. Signal to noise ratios to the isotype control antibody GSM238-B7 scFv-mouse-Fc 
and to BSA are plotted. light grey dots: samples that did not pass the selection criteria; dark grey dots: samples 
that passed the selection criteria; red dots: samples that passed the selection criteria and identified as MSLN 





3.3.2 Panning in solution yielded more hit candidates than panning in MTP 
format 
Phage display panning is often performed via immobilization of antigen or antibody on a 
surface and addition of a phage library of possible interaction partners43,49. However, 
adsorption to hydrophobic surfaces can have an impact on protein structure and binding 
to a surface reduces the accessible interaction area. Another possibility is to first allow 
both interaction partners to interact in solution and then capture them to a surface later, 
e.g. by using magnetic beads. To assess the significance of this factor for ORFeome 
display, panning on immobilized antibodies in MTP format was compared to panning in 
solution.  
Two antigen phage display pannings were performed for each of the three HCT antigen 
libraries described in section 2.2.1. First, antibody SuW57-D11 in the scFv-mouse-Fc 
format was immobilized on the surface of an MTP and second, the same antibody was 
incubated with the antigen library in solution and later captured using protein A magnetic 
beads. After two rounds of panning, 92 randomly picked clones of each panning strategy 
and each library were screened by ELISA using the secreted antigen-pIII fusion proteins. 
Cut-off values for signal to isotype control and signal to BSA control ratios were set to 5 
and 10, respectively, for both experiments. Panning in MTP format yielded only one 
positive clone whereas panning in solution yielded 41 positive clones from all three 
selections (Figure 3-6). Of these clones, 21 were sent for Sanger sequencing and all 
identified as MSLN mRNA sequences in BLASTn analysis. This comparison shows that 
panning in solution was more efficient for the selection of interaction partners in the current 
setting. 
 
Figure 3-6 – Peptide screening ELISA for MSLN panning in two formats: Peptides selected by MTP 
panning or panning in solution were tested for their specific binding to anti-mesothelin antibody SuW57-D11 
scFv-mouse-Fc as secreted antigen-pIII fusion proteins in ELISA. Signal to noise ratios to the isotype control 
antibody GSM238-B7 scFv-mouse-Fc and to BSA are plotted. light grey dots: samples that did not pass the 
selection criteria; dark grey dots: samples that passed the selection criteria; red dots: samples that passed the 
selection criteria and identified as MSLN sequences after Sanger sequencing 
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3.3.3 Phage ELISA versus antigen ELISA 
Individual clones identified by panning can be screened for antibody binding by ELISA, 
either in form of secreted antigen-pIII fusion proteins or as antigen presenting phage 
particles. To check which approach performs better, the three times 92 clones picked from 
the panning in solution experiment described in 3.2 were subjected to antigen ELISA and 
phage ELISA in parallel. Cultivations for soluble expression of antigen-pIII fusion protein 
or Hyperphage packaging were inoculated from the same starting cultures. Non-purified 
cultivation supernatants were used for ELISA. 
Compared to antigen ELISA, phage ELISA resulted in higher overall signal and improved 
resolution of data points, facilitating more confident hit selection. Applying the same cut-
off values as before (see section 3.2), phage ELISA identified 77 positive clones (Figure 
3-7). Of these, 51 were sent for Sanger sequencing and 47 identified as mesothelin mRNA 
sequences in BLASTn analysis, compared to 21 positive sequence identifications from 41 
positive clones after antigen ELISA. Interestingly, there was only a small overlap of clones 
that are identified as MSLN mRNA sequences by both methods with 7 hits in 276 screened 
and 65 sequenced clones (Figure 3-8). A prevalence of different average insert sizes or of 
specific parts of the MSLN sequence was not observed for any of the two methods. Taken 
together these data suggest that phage ELISA is the favourable screening method for 
identifying hit candidates from antigen libraries using antibodies as capturing partner.  
 
 
Figure 3-7 – Antigen versus phage screening ELISA: Peptides selected by panning in solution were tested 
as antigen-pIII fusion proteins or Hyperphage packaged single clones for their specific binding to anti-
mesothelin antibody SuW57-D11 scFv-mouse-Fc in ELISA. Signal to noise ratios to the isotype control 
antibody GSM238-B7 scFv-mouse-Fc and to BSA are plotted. Light grey dots: samples that did not pass the 
selection criteria; dark grey dots: samples that passed the selection criteria; red dots: samples that passed the 






Figure 3-8 – Confirmed MSLN sequences: Venn diagram showing the shares of confirmed MSLN 
sequences identified by antigen ELISA (red), phage ELISA (dark grey) and both methods (light red). 65 out of 
276 screened clones were sequenced, 2 were not identified as MSLN sequences and 2 were disregarded due 
to low sequencing quality 
 
3.3.4 Panning in 96-well format 
For reliable identification of targets that have a general relevance for patients in a given 
disease context, large sample numbers are needed. Performing panning of patient specific 
antigen libraries against the according patient antibody repertoires for dozens of patients 
is very time consuming. Even more so, if every patient library has to be cross selected with 
antibodies from every other patient individually. Therefore, it was tested if antigen panning 
in solution could also be performed in a 96 well-plate format to decrease overall handling 
time and make the method high throughput applicable without the need for equipment 
other than a 96-channel pipette and a magnetic plate. 
A pool of antigen libraries was selected against recombinant oligoclonal antibody mixtures 
derived from TIBC from Yuhan011 and Yuhan012 (kindly provided by Melanie Philippi), 
against serum from Yuhan008 or against the anti-MSLN antibody SuW57-D11 (for 
control). The HCT116 S4 cell line antigen library was selected against SuW57-D11 as an 
additional control. A total of 192 clones from each selection were tested in phage ELISA. 
Clones were regarded as positive, when their signal to noise ratios for isotype and BSA 
control were greater than 5 and 10, respectively. 
Selection of antigen fragments from Yuhan011, yielded 14 positive clones. Twelve of those 
were sequenced but did not show any enrichment of sequences that could be aligned to 
a single mRNA reference (Figure 3-9 A). This lack of enrichment made it impossible to 
choose a likely target candidate, since the enrichment should be an indicator for specific 
binding. For the Yuhan012 library, eight clones were positive in ELISA and 6 of those were 
sequenced. All sequences mapped to different mRNAs using BLASTn and were not 
showing enrichment of a certain gene. However, one of the sequences selected mapped 
to MMP9 which has also been enriched in other Yuhan012 selections (Figure 3-9 B). Out 
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of the 49 ELISA-positive clones from the Yuhan008 antigen library selection a total of 12 
were sequenced. Despite very strong ELISA signals and high signal to noise ratios, no 
enrichment of sequences corresponding to a single gene could be seen (Figure 3-9 C). 
For the samples selected against anti-MSLN antibody SuW57-D11 all ELISA-positive and 
DNA sequenced clones (n = 5 and n = 6) could be mapped to MSLN mRNA (Figure 3-9 D 
and E).  
Taken together, these data show that selection of binding peptides from patient derived 
cDNA fragment antigen libraries against monoclonal scFv-Fc antibodies by panning in 
solution is possible in a multi-sample paralleled approach. However, success of the 
selection process seems to greatly depend on the combination of starting library 
composition (i.e. single patient library or pooled library from several patients) and antibody 
format (i.e. monoclonal antibody, oligoclonal mixture of antibodies of unknown specificity 
or patient serum) used for selection, as demonstrated by the varying outcome in similar 







Figure 3-9 – Phage screening ELISA for pannings in 96-well format: Peptides selected by panning in 
solution were tested as Hyperphage packaged single clones for their specific binding to different antibodies 
and antibody mixtures in phage ELISA. Peptides selected from a pooled patient antigen library were tested 
against (A) an oligoclonal mixture of recombinant scFv-mouse-Fc antibodies from Yuhan0011 TIBC, (B) an 
oligoclonal mixture of recombinant scFv-mouse-Fc antibodies from Yuhan0012 TIBC (C) Yuhan008 patient 
serum, (D) monoclonal anti-mesothelin antibody SuW57-D11 in scFv-mouse-Fc format. (E) Peptides selected 
from HCT116 S4 antigen library were tested against monoclonal anti-mesothelin antibody SuW57-D11 in scFv-
mouse-Fc format. Signal to noise ratios to the isotype control antibody GSM238-B7 scFv-mouse-Fc and to 
BSA are plotted. light grey dots: samples that did not pass the selection criteria; dark grey dots: samples that 
passed the selection criteria; red dots: samples that passed the selection criteria and were analysed by Sanger 
sequencing; labels: gene symbols of the best match from NCBI-BLASTn for the selected sequence 
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3.3.5 Using NGS as an alternative screening method 
Despite multiplexed pannings comprising up to 96 samples were shown to be possible, 
the next bottleneck of the technology was the need to screen a large number of individual 
clones from many individual pannings. Usually, binding specificity of single clones is 
analysed by ELISA. Positive clones are then sequenced to check their identity and 
enrichment. Performing ELISA of several hundred clones for each of the 96 selections, i.e. 
of more than 25,000 clones individually, is possible but laborious and time consuming. 
Moreover, expression or display of antigens during screening may be insufficient to 
achieve detectable signals in ELISA, resulting in false negative results. Alternatively, by 
using next generation sequencing (NGS), millions of sequences could be analysed in a 
single experiment potentially yielding information about all antigen clones enriched after 
selection. The hypothesis is that despite binding specificity is not analysed in a separate 
functional assay, the enrichment of sequences during panning could be indicative of the 
relevance of the encoded polypeptide. 
In order to check whether NGS can be used as a surrogate screening method, DNA from 
either amplified or eluted phage particles from different pannings was analysed. Yuhan007 
and Yuhan011 libraries were selected against corresponding oligoclonal pools of          
scFv-mouse-Fc antibodies and Yuhan008 library was selected against patient serum. For 
Yuhan007 and Yuhan008, pannings were run in three independent parallel samples for 
each library. The whole volume of eluted phage particles was collected and analysed after 
one, two or three rounds of selection, respectively. For Yuhan011, a single panning was 
performed. Re-amplified phage particles of the second round and eluted phage particles 
of the third round of selection were sampled for analysis. 
The results demonstrated that panning steps altered the distribution of genes in all 
analysed samples, as expected. Across all samples, individual selection rounds show high 
variation in gene distribution and gene diversity decreases with increasing selection 
rounds. In selections carried out with oligoclonal recombinant antibody mixtures, genes 
that were present in high numbers in the original unselected libraries are still present in 
abundance after the first selection round but they diminish or are lost in later selection 
rounds (Figure 3-10 A-D, Figure 3-11 A-D, Figure 3-12 A-C). Meanwhile, genes that show 
high enrichment after the second and third selection round are not necessarily enriched 
after the first selection round. This shows the necessity for at least two rounds of selection 
in this sample type. In the selections carried out with patient serum, the first round already 




To select candidates for further investigation, the 100 genes with the highest read counts 
were analysed for each selection round. Read counts measured for a gene after selection 
were divided by the read counts for the same gene in the unselected library to yield an 
enrichment factor. If a gene was not detected in the unselected library, read counts were 
set to 1 to generate the enrichment factor. Genes with a read count greater than 20,000 
(roughly two times the average read count) and an enrichment factor of more than 200 
were regarded as hit candidates. 
For Yuhan007 the most abundant cDNA sequences after the second selection round map 
to WWC2, SHTN1, MTCO2P12, SPRR3 and HSPA8 genes (Supplementary Table 3). 
Interestingly, while SHTN1 is also the second most frequent gene after the third round, 
WWC2 and MTCO2P12 are lost and SPRR3 and HSPA8 are lowly represented. Instead 
PRKDC, EFHD2, CHD8 and PRRC2B sequences were enriched (Supplementary Table 
4). This result shows that selections with complex antigen libraries and antibody mixtures 
are not entirely reproducible. Taking the enrichment factors into account, WWC2, SHTN1, 
PRKDC, EFHD2, UBE2L6 and CHD8 emerge as hit candidates (Figure 3-10 E). 
For Yuhan008 the most enriched sequences after the second panning round map to the 
PRRC2B gene, followed by EEA1, TOP1MT, CHD8 and UBE2L6 (Supplementary Table 
7). After the third round TOP1MT, EEA1, IGHV3-65, CHD8 and UBE2L6 are most 
abundant (Supplementary Table 8). Due to their respective enrichment factors, all these 
genes qualify as hit candidates (Figure 3-11). The enrichment of EEA1 and IGHV3-65 is 
in accordance with results gained from screening ELISA after an identical panning (see 
section 3.4.2). 
For Yuhan011, MMP9 and MYC sequences are the most abundant after the second 
selection round and after the third round they make up roughly 99 % of all analysed 
sequences (Figure 3-12 C and D; Supplementary Table 10 and 11). MMP9 enrichment 
was also confirmed by screening ELISA after an identical panning (see section 3.4.1).  
These results show, that NGS enables monitoring de-/enrichment processes during 
panning and that it may be used as an alternative screening method. In some but not the 
majority of cases, it yielded the same hits as functional screening by ELISA. However, 
analysis of only one of the selection rounds might not be enough to draw correct 







Figure 3-10 – Yuhan007 sequence enrichment: Three individual pannings were performed on an oligoclonal 
mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan007 using the antigen phage library 
from the same patient. Eluted phage particles were sampled after round one, two and three, respectively. 
Unselected library and elution samples were analysed via NGS. Heatmaps show read counts across all 
samples for the 100 genes with the highest read counts in (A) the unselected library, (B) eluted phage after 
round one, (C) eluted phage after round two and (D) eluted phage after round three. (E) Read counts of the 
100 genes with the highest read count were plotted against the enrichment factor (reads per gene in sample 
divided by reads per gene in unselected library). Grey dots: genes that did not pass the selection threshold, 








Figure 3-11 – Yuhan008 sequence enrichment: Three individual pannings were performed on patient serum 
from Yuhan008 using the antigen phage library from the same patient. Eluted phage particles were sampled 
after round one, two and three, respectively. Unselected library and elution samples were analysed via NGS. 
Heatmaps show read counts across all samples for the 100 genes with the highest read counts in (A) the 
unselected library, (B) eluted phage after round one, (C) eluted phage after round two and (D) eluted phage 
after round three. (E) Read counts of the 100 genes with the highest read count were plotted against the 
enrichment factor (reads per gene in sample divided by reads per gene in unselected library). Grey dots: genes 
that did not pass the selection threshold, red dots: genes that passed the selection threshold. Genes are 







Figure 3-12 – Yuhan011 sequence enrichment: Panning was performed on an oligoclonal mixture of 
recombinant scFv-Fc antibodies derived from TIBC from Yuhan011 using the antigen phage library from the 
same patient. Phage particles were sampled after amplification of selection round two and after elution of 
selection round three. Unselected library and selected samples were analysed via NGS. Heatmaps show read 
counts across all samples for the 100 genes with the highest read counts in (A) the unselected library, (B) 
amplified phage particles after round one and (C) eluted phage after round three. (D) Read counts of the 100 
genes with the highest read count were plotted against the enrichment factor (reads per gene in sample divided 
by reads per gene in unselected library). Grey dots: genes that did not pass the selection threshold, red dots: 





3.4 Identification of target candidates  
In order to identify peptides, which have the potential to be used as therapeutic targets, 
biomarkers or simply just being tumor associated proteins of interest in the context of head 
and neck cancer, antigen phage libraries were panned against either oligoclonal mixtures 
of TIBC derived scFv-Fc antibodies (kindly provided by Melanie Philippi) or against patient 
sera.  
3.4.1 Panning on oligoclonal scFv-Fc 
The antigen phage library of Yuhan012 was panned on an oligoclonal mixture of 
recombinant scFv-Fc antibodies derived from TIBC from the same patient. Screening 
ELISA was performed with 192 single clones each from the amplified antigen phage 
particles of the second round and the phage particles eluted after the third round of 
panning. Clones were regarded as positive when their signal to noise ratio for isotype and 
BSA control were both greater than 5 (Figure 3-13). A total of 18 clones was chosen for 
sequencing and 16 of these clones were identified as an MMP9 fragment by BLASTn 
analysis. The remaining two samples were discarded due to low sequencing quality. When 
the different selected MMP9 mRNA sequences are aligned, they share a 48 bp 
overlapping sequence. This suggests that this peptide stretch contains the epitope of the 
antibody or antibodies that caused the enrichment and selection of the MMP9 peptides.  
 
Figure 3-13 – Phage screening ELISA for Yuhan012 panning: Peptides selected from Yuhan012 antigen 
library by panning in solution were tested as Hyperphage packaged single clones for their binding to a 
corresponding recombinant oligoclonal scFv-Fc antibody mixture from TIBC in ELISA. Signal to noise ratios to 
the isotype control antibody GSM238-B7 scFv-mouse-Fc and to BSA are plotted. light grey symbols: samples 
that did not pass the selection criteria; dark grey symbols: samples that passed the selection criteria; red 
symbols: samples that passed the selection criteria and identified as MMP9 mRNA sequences after Sanger 
sequencing; dots: single clones sampled from the amplified phage particles after the second panning round; 




3.4.2 Panning on patient serum 
The antigen phage library of Yuhan008 was panned on serum of the same patient. 
Screening ELISA was performed with 192 single clones each from the amplified antigen 
phage particles of the second round and those eluted after the third round of panning. 
Clones were regarded as positive, when their signal to noise ratios for isotype and BSA 
control were both greater than 2. A total of 42 clones was chosen for sequencing and 16 
of these clones were identified as an EEA1 fragment by BLASTn analysis. Again, a 
sequence overlap of the different antigen fragments was found in multiple sequence 
alignment. The remaining 26 sequences were all identified as an identical mRNA 
sequence corresponding to an immunoglobulin heavy chain variable region (IGHV3-65). 
It is noticeable that the IGHV sequences are much more prevalent after the third panning 
round, whereas the EEA1 sequences have higher occurrence after the second panning 
round (Figure 3-14). 
 
Figure 3-14 – Phage screening ELISA for Yuhan008 serum panning: Peptides selected from Yuhan008 
transcriptome library by panning in solution were tested as Hyperphage packaged single clones for their 
binding to serum from the same patient in ELISA. Signal to noise ratios to the isotype control antibody 
GSM238-B7 scFv-mouse-Fc and to BSA are plotted. light grey symbols: samples that did not pass the 
selection criteria; dark grey symbols: samples that passed the selection criteria; red symbols: samples that 
passed the selection criteria and identified as EEA1 mRNA sequences after Sanger sequencing; teal symbols: 
samples that passed the selection criteria and identified as IGHV3-65 mRNA sequences after Sanger 
sequencing. dots: single clones sampled from the amplified phage particles after the second panning round; 






This thesis describes a new approach for the discovery of potential novel biomarkers and 
therapeutic targets for cancer immunotherapy using cDNA peptide libraries from fresh 
tumor specimens that are selected against autologous antibody repertoires from tumor 
infiltrating B cells (TIBC) in addition to autologous patient sera. Phage display peptide 
libraries have been used extensively in the search for new therapeutic targets, biomarkers 
and antibody epitopes29,37,50,51. Commercially available short peptide libraries enclose 
large diversities of up to 109 unique sequences (for example Ph.D.™-12 from New England 
Biolabs), yet they are of artificial design and only yield linear epitopes. Other common 
approaches, like the SEREX technology52, use cDNA libraries derived from frozen or fixed 
tissues or cell lines and screen the encoded peptides against patient sera. These libraries 
represent the natural distribution of expressed genes more closely than synthetic libraries. 
However, in the case of cell lines, they originate from a model system. Fresh and untreated 
tissues represent patient biology and disease. The use of fresh unfixed tissue allows 
separation of different cell types prior to downstream treatments and analysis. These cells 
are viable and may be propagated if so desired. In this study, this advantage was used to 
isolate tissue-residing B cells to access the local antibody repertoire of the tumor tissue. 
Combined with highly diverse cDNA derived protein fragment libraries these antibodies 
can help to identify new epitopes or proteins that are relevant for individual patient biology 
or for the general disease context. 
 
4.1 Antigen library quality 
The new pTSD3 vector allows efficient unidirectional cloning of cDNA libraries created 
from fragmented mRNA. Theoretically, this way of cloning should yield roughly 11 % of 
sequences in a library that contain ORFs that match the natural ORFs of proteins. 
Unfortunately, comparing pTSD3 insert sequences to ORFs of proteins of the NCBI 
reference protein database revealed that this is only the case for 2 % of sequences. This 
is due to a high percentage of sequences containing stop codons. While the presence of 
stop codons was expected, higher numbers may occur due to non-mRNA contaminations 
within the library preparation or as a result of RNA fragmentation. If fragmentation does 
not yield fragments with an equal distribution of all three possible reading frames, the 
occurrence of correct ORFs may be reduced. However, the rate of correct ORFs is rescued 
via Hyperphage and increases to 57 % after packaging. 
The antigen libraries created in this work consist of 1.7 x 107 - 1 x 108 antigen clones and 
are comparable in size with other published cDNA libraries29,53. According to NGS analysis 
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the highest number of unique genes represented with more than 10 reads in a single library 
was 7,169. However, this is based on 4.6 x 106 total reads for the according sample 
(Yuhan007) which covers only 4.6 % of the theoretical maximum of 1 x 108 antigen clones. 
Deeper sequencing runs, i.e. interrogation of a higher number of sequences, would likely 
reveal greater gene coverage. This is demonstrated by the presence of gene sequences 
in samples after panning that were not detected in the unselected libraries. The human 
transcriptome consists of approximately 21,000 genes54. Considering that roughly 11,000 
to 13,000 of these genes are actively transcribed in a given tissue type55, the presented 
antigen library preparation process may be sufficient in order to achieve complete 
transcriptome coverage. If necessary, input RNA amounts could be increased and several 
separate library preparations from the same tissue sample could be combined to increase 
the number of represented genes.  
Many of the highly represented genes, for example those coding for Beta-actin (ACTB), 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), ribosomal proteins, or histones 
are housekeeping genes with equal representation in all libraries. Others, for example 
genes coding for CEA Cell Adhesion Molecule 5 (CEACAM5), Carboxylesterase 1 (CES1) 
or Small proline rich protein 3 (SPRR3) are more tissue-/cell type-specific and only highly 
represented in a single libraries. It is not clear whether these differences arise due to the 
heterogenic nature of the biological samples or due to an amplification bias during antigen 
library preparation. By applying emulsion PCR for unbiased amplification of antigen 
fragments prior to library cloning the likelihood of an amplification bias may be reduced. 
Additionally, this could preserve low-copy transcripts and increase gene coverage56.  
ORF enrichment using Hyperphage resulted in libraries with very high percentages of 
ORFs. The limitations in regards to insert size after Hyperphage packaging are in 
accordance with the work of other groups57. However, it is unlikely that the size of the 
secreted polypeptide-pIII fusion protein is the limiting factor, since larger polypeptides can 
efficiently be displayed on Hyperphage, as exemplified by scFv antibody phage display42. 
Additionally, several mesothelin (MSLN) inserts of more than 400 bp length were found 
during the SuW57-D11 selections. The antigen libraries were created using randomly 
fragmented RNA. For the resulting nucleotides the likelihood for the occurrence of a stop 
codon increases with length. It may be that a large percentage of longer inserts do not 
yield functional pIII due to an early stop codon and are therefore not packaged into 
Hyperphage. By cloning a cDNA library that was pre-selected for ORFs into a phagemid 





4.2 Technology validation 
It was shown that phage ELISA is the superior screening method compared to antigen 
ELISA regarding signal strength and total number of identified true positive clones. A major 
advantage of phage ELISA is the signal amplification through detection of major coat 
protein pVIII via the secondary antibody which increases sensitivity. This facilitates 
improved detection of antigen phage particles from non-purified culture supernatants. 
Additionally, multivalent display of peptides on Hyperphage can cause avidity effects that 
facilitate the detection of weak interaction partners. The increased detection of low affinity 
interactions is desirable since the aim of the antigen screening is the identification of 
interaction partners, regardless of binding kinetics. 
The enrichment of MSLN sequences using anti-MSLN antibody SuW57-D11 provides 
proof of principle for the reproducible selection of specifically bound polypeptide antigens 
from antigen phage libraries derived from fresh patient tissue. The presence of several 
different selected sequences that overlap partially allows identification of a possible 
minimal epitope of the used antibody. More detailed knowledge of the epitope is important 
for development of an antibody drug after target candidate identification. 
Epitope structure is a great issue when selecting polypeptides and protein fragments in an 
in vitro setting. The presented approach employs E. coli and phage for the secretion and 
presentation of antigenic protein fragments. These simple organisms lack the complex 
folding machinery of mammals and many protein fragments secreted under these 
conditions will not assume their natural fold. It must be considered that foreign folds and 
linear epitopes may be the outcome of this approach. However, sequence alignment of all 
MSLN fragments selected with SuW57-D11 in several experiments revealed a 180 bp i.e. 
60 amino acid overlapping region (Supplementary Figure 1). This region is identical in 
sequence with the published 3D epitope structure of a therapeutic anti-MSLN antibody58. 
This shows that at least some antigen fragments may assume a tertiary structure or even 
a natural fold when their intrinsic stability is high enough. Nonetheless, moving the 
presentation of protein fragments from patient tissue derived antigen libraries to a 






4.3 Selection of antigen fragments from tumor derived antigen 
libraries 
Using an oligoclonal mixture of antibodies generated from TIBC isolated from head and 
neck cancer tissue, MMP9 peptide fragments were enriched. MMP9 has strong 
implications in various cancers59,60 and several therapeutics targeting MMP9 and other 
metalloproteinases are currently being developed61,62, validating the presented approach 
for the identification of peptides relevant in the context of head and neck cancer. After 
selection of MMP9 peptides from the antigen libraries, recombinant full-length protein was 
used to generate MMP9 specific antibodies using recombinant antibody libraries created 
from TIBC (Melanie Philippi, personal communication). This shows that the selection of 
MMP9 was based on the antibody repertoire enclosed in the patients’ tissues. 
Interestingly, sequence analysis revealed that the anti-MMP9 antibodies originated from 
antibody libraries from several different patients, providing evidence that MMP9 peptide 
selection was not a patient specific artefact (Melanie Philippi, personal communication).  
Besides recombinant antibody mixtures derived from patient tissue, autologous patient 
serum was used to select antigen fragments. Due to reproducible enrichment of several 
overlapping peptides, EEA1 was proposed as a likely target candidate by this approach. 
The sequence overlap is indicative of a specific interaction with the encoded peptide 
epitope as seen for the anti-MSLN antibody. Furthermore, it decreases the likelihood that 
the enrichment was caused by a technological bias. The high prevalence of a single IGHV 
sequence enriched during the same selection process is a likely example for a bias in 
display and amplification. Antibody fragments can easily be expressed in E. coli and 
presented on phage. Such an advantage can lead to the enrichment of a peptide in phage 
display without specific binding to the selecting interaction partner63. 
EEA1 has been shown to be overexpressed in aggressive prostate tumors64, but otherwise 
not much information exists about its implications in cancer. EEA1 is involved in early 
endosome formation and trafficking and regulates endosome fusion events. High EEA1 
expression causes an increase in endosome fusion events, leading to the formation of 
much larger endosomes65. These endosomes can become multivesicular bodies and fuse 
with the plasma membrane. Thereby they release exosomes, that have been shown to 
promote tumor growth and metastasis formation66,67. Blocking EEA1 may decrease the 
number of exosomes that are released from cells and alleviate their tumorigenic effects by 
reducing the formation of large multivesicular bodies. 
Besides EEA1, many other intracellular proteins were selected as interaction partners of 




the patient’s immune system reacted to intracellular material. A reason for that may be the 
unusual exposure of proteins on the cell surface due to apoptotic events in the tumor68. An 
additional upregulation of these proteins in the tumor could further increase the chance of 
a local immune response. Some of the selected intracellular proteins are associated with 
actin filaments and microtubules of the cytoskeleton. Changes in the cytoskeleton are 
crucial for epithelial-mesenchymal transition, cell motility and finally metastasis formation. 
Actin filaments are especially important for the formation of invadopodia that are needed 
to cross physiological barriers69. The protein cortactin has been shown to be required for 
initiation and stabilization of invadopodia. SHNT1, which has been selected using 
oligoclonal mixtures of TIBC derived antibodies (see section 3.3.5.) is normally involved in 
neuronal polarization and neurite outgrowth. However, it interacts with cortactin to promote 
signal-force transduction70. Its presence in head and neck cancer tissues could suggest 
an implication of SHTN1 in cancer cell motility. These results imply that there may be a 
need for more efficient intracellular drug delivery systems to target dysregulated and 
possibly mutated proteins inside of cancer cells. 
As exemplified by the experiment in the 96-well format, the selections using recombinant 
oligoclonal antibody mixtures or patient sera are not always reproducible. The 
stoichiometry of this approach is very complex. Millions of different protein fragments 
interact with up to thousands of different antibodies to reach the interaction with the highest 
affinity. The resulting binding equilibria may change drastically if one of the complex 
mixtures of interaction partners is altered. In the mentioned experiment, several antigen 
libraries were pooled prior to selection. While this did not affect the selection of MSLN 
fragments with a single antibody, the selections using recombinant oligoclonal antibody 
mixtures or patient sera failed to yield the same results as when tested against antigen 
libraries from the same patient. 
 
4.4 Relevance of identified protein fragments 
Potential new therapeutic targets and biomarkers identified by application of ORFeome 
display in combination with TIBC derived antibodies and patient sera originate from an 
interaction of proteins with patient antibody repertoires. However, a detailed scientific 
process is needed to validate their relevance in the disease setting. Promising novel 
targets, by their definition, are not well described. Therefore, finding information on their 
implications in cancer through literature research is challenging. Harvesting gene 
expression and proteomics data from publicly available databases can be partially 
automated and may help to refine the list of candidates but hard evidence can only be 
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generated through a series of experiments. The first step would be the generation of 
recombinant antibodies with strong affinity for the suggested epitope. With the presented 
approach, target binding antibodies are readily available from the TIBC libraries with a high 
degree of certainty and in a short period of time. These antibodies then need to be tested 
for their ability to specifically bind to cancerous tissue or specific cells therein. Classic 
immunohistochemistry on tissue slides is still an acknowledged standard in this regard. 
Passing this stage, the new target and antibody have the potential to be a new biomarker 
or diagnostic tool, respectively. Whereas molecular characteristics of the antibody can be 
modified quite easily, functionality of the antibody is key for its consideration as a 
therapeutic agent. Besides performing cytotoxicity and internalization assays, the ability to 
effectively carry cytotoxic payloads should be scrutinized71. Such measures have been 
impeded by time and budget restrictions for the target candidates found in this study but 
will be considered for future projects. Anyhow, providing evidence for the therapeutic 
relevance of a target is just a small part of the necessary investigations. A deep 
understanding of the molecular biology of the target is needed to predict a mode of action 
and possible side effects of a therapeutic intervention. This includes, among others, the 
elucidation of its basic function within the cell and regulation of its gene expression and 





4.5 Implications of next generation sequencing 
NGS has previously been used to gain better insight into the selection process and to 
replace conventional screening methods in phage display72,73. It enables a more complete 
view of the selection outcome and the implementation of high throughput and multi-sample 
parallelized approaches. In this study, NGS has been used for the same reasons and to 
test its compatibility with the presented workflow. By comparing sequence frequencies in 
the unselected and selected samples an enrichment factor can be calculated. Together 
with the total read count for a gene after selection this factor helps to discriminate likely hit 
candidates. For this, deep sequencing of the unselected library to detect all enclosed 
genes is of great importance since missing read count values hinder correct calculation of 
the enrichment factor. To further refine the selection of specifically enriched gene 
sequences several negative controls should be included in the panning procedure to rule 
out those clones that prevail due to propagation advantage or binding to some part of the 
selection system.  
Whereas for small peptide libraries, a single round of panning seems to be enough to 
reveal candidates via NGS74, the data from this study suggests that two rounds of selection 
are needed for libraries with larger peptides that are selected against complex mixtures of 
antibodies. After the first panning round gene frequencies did not change significantly and 
genes that were highly enriched after round two and three were sometimes even 
represented with fewer sequences than in the unselected library. A third panning round 
may confound the results by enabling unspecific peptides with an amplification advantage 
to reach very high copy numbers63. This is exemplified by the immunoglobulin sequence 
selected from the Yuhan008 library which replaces EEA1 as the most frequent gene after 
three panning rounds. When patient sera are used for selection, strong enrichment can 
already be seen after the first selection round. However, the most highly represented 
genes are not the same as after two and three rounds of panning, indicating increased 
reproducibility of selection after performing more than one round of selection 
Thus far, NGS has confirmed EEA1 and MMP9 sequences as one of the three most 
enriched sequences in their according selections. WWC2 and SHTN1 that showed strong 
enrichment in the NGS data for Yuhan007 have also been selected previously in 
conventional screening methods (data not shown). By setting cut-off values for total read 
count and enrichment factor these genes could be discerned from other frequent 
sequences in the analysis. This shows that NGS can replace conventional screening in a 
high throughput application. However, for chosen antigen fragments specific binding to an 




This work provides proof of principle that tumor relevant proteins can be identified using 
tumor antigen phage display libraries and TIBC-derived antibody repertoires. At this point 
in time, the application of this technology resides at single patient level and individual 
findings and insights. Higher sample numbers should be processed for the discovery of 
proteins that are relevant for many patients or specific patient groups that are defined by 
disease characteristics. As demonstrated, the method is compatible with high-throughput 
applications and larger amounts of samples can easily be processed. Furthermore, the 
technology can be applied to other types of cancer and act as a target discovery platform. 
It may be useful for the discovery process to create antibody libraries that keep the natural 
pairing of heavy and light chain of TIBC derived antibodies. This would likely reduce the 
complexity of the antibody mixtures used for selection and thereby improve efficiency. 
Another advancement would be single B cell cloning of antibody sequences. This would 
offer the possibility to conduct monoclonal selections on the antigen libraries, which has 
proven to be the more powerful and reproducible approach. Additionally, the identification 
of many interaction partners of TIBC antibodies will enable conclusions about the local 
immune reaction. Investigating the antibody repertoires of TIBC populations might give 
information about why they have beneficial or detrimental influences on clinical outcomes, 
depending on the biological context4,75. 
NGS is superior to ELISA as a first line screening in terms of throughput and information 
yield, but ELISA should still be used to confirm binding of the selected target candidates 
to the antibodies used for selection. By designing and maintaining a bioinformatics 
pipeline, increasing amounts of data can be analysed and integrated which means that the 
impact of NGS analyses further improves over time. Besides a better understanding of the 
antigen selection process this will enable insights into individual patient biology via 
analysis of the unselected libraries. Since the antigen libraries are generated using 
methods similar to RNA sequencing library generation, comparative transcriptome 
analysis should be possible, provided that a sufficient sequencing depth is reached. 
Taken together, the information provided in this study may be used to create a target 







This study presents an approach to identify proteins with relevance in tumor biology by 
selecting protein fragments from fresh tumor tissue derived antigen libraries against 
patient sera and antibody repertoires derived from tumor infiltrating B cells. These proteins 
have the potential to become new biomarkers or therapeutic targets. Applying this 
technology, the well-known therapeutic target MMP9 was selected besides newly 
proposed targets, for example EEA1, WWC2 and SHTN1. While validation protocols for 
these new targets still need to be set up, the groundwork for a potential target discovery 
platform is laid out. The method is high throughput applicable and screening efforts can 
be reduced by implementing sophisticated technologies like NGS. The latter approach also 
yields the possibility for more in-depth analyses and might allow insights into disease 
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8.1 Supplementary data 
Supplementary Table 1 – Yuhan007 unselected library NGS data: Three individual pannings were 
performed on an oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan007 
using the antigen phage library from the same patient. Eluted phage particles were sampled after round one, 
two and three, respectively. Unselected library and elution samples were analysed via NGS. Read counts 
















MT-ND2 28389.00 26750.17 675.83 63.63 
GAPDH 13376.28 15961.04 4511.44 119.31 
KRT6A 11176.96 15148.62 2231.49 0.00 
SPRR3 10501.40 11279.68 14870.43 757.21 
TMSB4X 10193.27 8729.36 0.00 0.00 
EEF1A1 7264.28 4131.65 8.31 0.00 
KRT17 6898.29 7122.05 1537.04 230.66 
MT-CO3 5060.19 8061.56 4123.28 127.26 
RPLP0 4777.76 3215.78 0.00 0.00 
KRT5 4610.00 4951.33 250.05 3.18 
FTH1 4285.91 3831.75 362.84 3.18 
ANXA1 4106.91 3864.46 274.54 1.59 
RNA18S5 4104.36 4784.29 2573.12 157.49 
PABPC1 4102.54 3035.57 179.24 386.56 
ACTB 4052.64 5988.23 493.70 1253.28 
MT-ND4 3792.75 5614.77 0.87 0.00 
CTTN 3770.88 3153.21 493.99 1.59 
KRT15 3594.47 3430.46 951.26 1221.72 
KRT19 3432.08 5862.25 2597.60 173.39 














Supplementary Table 2 – Yuhan007 1st elution sample NGS data: Three individual pannings were 
performed on an oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan007 
using the antigen phage library from the same patient. Eluted phage particles were sampled after round one, 
two and three, respectively. Unselected library and elution samples were analysed via NGS. Read counts 
across all samples for the twenty genes with the highest read counts in the 1st elution sample are shown. 
Enrichment factors are calculated by dividing the read count for a gene in the eluted sample by the read count 




















MT-ND2 28389.00 26750.17 675.83 63.63 0.94 
GAPDH 13376.28 15961.04 4511.44 119.31 1.19 
KRT6A 11176.96 15148.62 2231.49 0.00 1.36 
SPRR3 10501.40 11279.68 14870.43 757.21 1.07 
TMSB4X 10193.27 8729.36 0.00 0.00 0.86 
MT-CO3 5060.19 8061.56 4123.28 127.26 1.59 
KRT17 6898.29 7122.05 1537.04 230.66 1.03 
MUC4 2698.65 6869.50 1206.56 0.00 2.55 
ACTB 4052.64 5988.23 493.70 1253.28 1.48 
KRT19 3432.08 5862.25 2597.60 173.39 1.71 
MT-ND4 3792.75 5614.77 0.87 0.00 1.48 
MT-ATP6 3294.67 5268.70 194.05 0.00 1.60 
KRT5 4610.00 4951.33 250.05 3.18 1.07 
RNA18S5 4104.36 4784.29 2573.12 157.49 1.17 
KRT16 3417.87 4540.29 541.20 1.59 1.33 
CD68 1313.08 4286.78 48.96 0.00 3.26 
MUC21 2737.18 4141.69 226.45 0.00 1.51 
EEF1A1 7264.28 4131.65 8.31 0.00 0.57 
ANXA1 4106.91 3864.46 274.54 1.59 0.94 






Supplementary Table 3 – Yuhan007 2nd elution sample NGS data: Three individual pannings were 
performed on an oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan007 
using the antigen phage library from the same patient. Eluted phage particles were sampled after round one, 
two and three, respectively. Unselected library and elution samples were analysed via NGS. Read counts 
across all samples for the twenty genes with the highest read counts in the 2nd elution sample are shown. 
Enrichment factors are calculated by dividing the read count for a gene in the eluted sample by the read count 




















WWC2 27.37 80.99 637029.62 0.00 23272.63 
SHTN1 37.40 37.92 81270.45 243226.50 2173.10 
MTCO2P12 0.13 0.00 15251.60 0.00 119795.29 
SPRR3 10501.40 11279.68 14870.43 757.21 1.42 
HSPA8 760.77 521.62 10454.23 35.00 13.74 
MT-ATP8 707.80 1298.67 8169.67 0.00 11.54 
STX6 258.69 541.55 8090.06 0.00 31.27 
SPRYD7 8.51 0.00 6214.85 0.00 729.95 
IFITM2 155.01 72.41 5183.82 0.00 33.44 
GAPDH 13376.28 15961.04 4511.44 119.31 0.34 
EEF1A1P5 33.79 0.00 4427.68 0.00 131.04 
NCL 1523.79 1542.38 4339.24 0.00 2.85 
USP11 105.83 39.53 4228.20 0.00 39.95 
ZNF512B 124.05 24.43 4206.34 0.00 33.91 
MT-CO3 5060.19 8061.56 4123.28 127.26 0.81 
MYH9 3377.86 3308.12 3707.98 6.36 1.10 
PRKDC 118.96 43.71 3153.66 345548.36 26.51 
RPS20 283.67 149.45 3140.55 0.00 11.07 
SPTBN1 445.28 533.52 2851.15 0.00 6.40 







Supplementary Table 4 – Yuhan007 3rd elution sample NGS data: Three individual pannings were 
performed on an oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan007 
using the antigen phage library from the same patient. Eluted phage particles were sampled after round one, 
two and three, respectively. Unselected library and elution samples were analysed via NGS. Read counts 
across all samples for the twenty genes with the highest read counts in the 3rd elution sample are shown. 
Enrichment factors are calculated by dividing the read count for a gene in the eluted sample by the read count 




















PRKDC 118.96 43.71 3153.66 345548.36 2904.77 
SHTN1 37.40 37.92 81270.45 243226.50 6503.65 
EFHD2 75.43 179.34 0.00 145602.13 1930.21 
CHD8 183.73 150.41 56.83 55452.86 301.82 
PRRC2B 335.31 52.71 20.11 44661.08 133.19 
UBE2L6 27.21 0.64 3.50 32292.75 1186.65 
UACA 18.54 0.00 179.24 14211.99 766.56 
HOOK3 24.11 6.11 0.00 13119.13 544.14 
XAF1 65.57 0.00 20.98 9834.18 149.99 
LMNB2 260.36 404.96 0.00 7048.73 27.07 
IGHV1-24 1.00 0.00 1.75 6079.95 6079.95 
EEA1 12.81 8.03 0.00 5539.08 432.37 
RALBP1 94.05 132.09 782.51 5187.52 55.16 
CEP164 25.70 6.11 0.00 3779.68 147.06 
HSPB1 408.20 604.22 0.00 3673.10 9.00 
CLDN4 768.31 303.40 0.00 2950.89 3.84 
ATF6 78.59 11.89 4.37 2712.27 34.51 
PARP10 169.80 0.96 143.39 2429.11 14.31 
YTHDF1 124.93 132.09 6.99 2386.16 19.10 




Supplementary Table 5 – Yuhan008 unselected library NGS data: Three individual pannings were 
performed on patient serum from Yuhan008 using the antigen phage library from the same patient. Eluted 
phage particles were sampled after round one, two and three, respectively. Unselected library and elution 
samples were analysed via NGS. Read counts across all samples for the twenty genes with the highest read 
















IGHG1 29639.85 1540.79 4211.78 755.82 
TMSB4X 28523.99 2492.23 0.93 1.55 
IGKC 15390.61 15753.67 0.00 0.00 
HSPA1A 10995.89 15.83 53.22 0.00 
HSPA1B 10164.28 0.00 0.00 4.65 
IGHA1 8462.14 0.00 0.00 0.00 
CD74 8310.08 208.60 1.87 0.00 
AL928742.1 
(Linc RNA) 
7680.61 1477.50 29045.21 225.04 
ACTB 7596.42 50355.58 0.93 20.15 
HSPA1A 7429.24 9950.23 0.00 0.00 
EEF1A1 7164.20 0.00 0.00 57.34 
HBA1 6870.07 4.24 91.50 0.00 
GAPDH 6174.60 0.32 85.90 159.61 
FTH1 5880.37 9072.72 94.30 23.24 
CD68 4804.90 0.00 0.00 0.00 
RNA18S5 4326.85 1479.82 0.00 1.55 
IGHG4 4218.92 0.32 1483.93 1.60 
HSPA1B 3753.62 0.00 0.00 0.00 
MYH9 3648.22 948.99 304.38 3.10 





Supplementary Table 6 – Yuhan008 1st elution sample NGS data: Three individual pannings were 
performed on patient serum from Yuhan008 using the antigen phage library from the same patient. Eluted 
phage particles were sampled after round one, two and three, respectively. Unselected library and elution 
samples were analysed via NGS. Read counts across all samples for the twenty genes with the highest read 
counts in the unselected library are shown. Read counts across all samples for the twenty genes with the 
highest read counts in the 1st elution sample are shown. Enrichment factors are calculated by dividing the read 




















XAF1 215.00 97209.35 29449.65 3526.97 452.14 
KRT16 640.13 69783.18 0.00 7.75 109.01 
CHD8 116.54 69780.61 123178.71 60843.37 598.76 
PRRC2B 212.88 65914.52 196604.53 34614.27 309.63 
ACTB 7596.42 50355.58 0.93 20.15 6.63 
IDE 11.65 41698.40 0.00 4.65 3578.00 
DGUOK 35.46 31895.56 0.00 1.55 899.56 
JUNB 3208.55 27934.13 17.74 0.00 8.71 
IVNS1ABP 1455.00 27337.31 0.93 0.00 18.79 
ANKRD36C 16.16 26736.30 98.97 0.00 1654.15 
RSRP1 152.76 26154.29 0.00 0.00 171.21 
PPIAP22 58.54 24244.65 0.00 0.53 414.12 
FOXP3 423.43 22220.86 0.00 0.00 52.48 
ELOA 53.54 19799.13 0.00 1.55 369.81 
DDX39A 183.50 19482.69 115.78 18.60 106.17 
IGKC 15390.61 15753.67 0.00 0.00 1.02 
CGN 5.58 15315.23 0.00 0.00 2744.74 
SBNO2 465.77 14357.55 553.68 0.00 30.83 
SCYL1 277.37 12040.76 1046.67 125.52 43.41 





Supplementary Table 7 – Yuhan008 2nd elution sample NGS data: Three individual pannings were 
performed on patient serum from Yuhan008 using the antigen phage library from the same patient. Eluted 
phage particles were sampled after round one, two and three, respectively. Unselected library and elution 
samples were analysed via NGS. Read counts across all samples for the twenty genes with the highest read 
counts in the unselected library are shown. Read counts across all samples for the twenty genes with the 
highest read counts in the 2nd elution sample are shown. Enrichment factors are calculated by dividing the 




















PRRC2B 212.88 65914.52 196604.53 34614.27 923.54 
EEA1 6.99 647.04 174022.19 212885.42 24887.13 
TOP1MT 23.10 0.00 152225.05 486378.16 6590.89 
CHD8 116.54 69780.61 123178.71 60843.37 1056.96 
UBE2L6 100.01 10091.58 80961.67 48616.74 809.51 
HSPB1 325.04 266.54 48751.04 10951.28 149.98 
XAF1 215.00 97209.35 29449.65 3526.97 136.97 
AL928742.1 
(Linc RNA) 
7680.61 1477.50 29045.21 225.04 3.78 
RALBP1 46.62 0.32 11619.84 7830.31 249.27 
IGHV1-24 34.44 0.97 11031.61 4066.25 320.30 
TNKS1BP1 139.35 0.00 10987.73 959.22 78.85 
CEP164 20.98 757.46 10406.94 17868.93 496.10 
DCAF15 46.40 849.52 10033.49 653.95 216.22 
PARP10 477.18 5007.97 8785.14 175.11 18.41 
IGHV3-65 0.02 27.03 7406.66 90174.42 436934.81 
DCAF6 61.38 6665.81 6157.72 4563.68 100.32 
ATF6 34.75 1121.22 5027.95 912.74 144.68 
ERO1B 35.26 527.93 4397.71 97.63 124.72 
IGHG1 29639.85 1540.79 4211.78 755.82 0.14 





Supplementary Table 8 – Yuhan008 3rd elution sample NGS data: Three individual pannings were 
performed on patient serum from Yuhan008 using the antigen phage library from the same patient. Eluted 
phage particles were sampled after round one, two and three, respectively. Unselected library and elution 
samples were analysed via NGS. Read counts across all samples for the twenty genes with the highest read 
counts in the unselected library are shown. Read counts across all samples for the twenty genes with the 
highest read counts in the 3rd elution sample are shown. Enrichment factors are calculated by dividing the read 




















TOP1MT 23.10 0.00 152225.05 486378.16 21058.71 
EEA1 6.99 647.04 174022.19 212885.42 30445.01 
IGHV3-65 0.02 27.03 7406.66 90174.42 5319582.49 
CHD8 116.54 69780.61 123178.71 60843.37 522.08 
UBE2L6 100.01 10091.58 80961.67 48616.74 486.10 
PRRC2B 212.88 65914.52 196604.53 34614.27 162.60 
CEP164 20.98 757.46 10406.94 17868.93 851.82 
HSPB1 325.04 266.54 48751.04 10951.28 33.69 
RALBP1 46.62 0.32 11619.84 7830.31 167.97 
DCAF6 61.38 6665.81 6157.72 4563.68 74.35 
IGHV1-24 34.44 0.97 11031.61 4066.25 118.06 
XAF1 215.00 97209.35 29449.65 3526.97 16.40 
NAA10 29.37 0.00 1610.62 2215.98 75.45 
TRNAU1AP 10.10 0.00 944.90 1094.04 108.32 
TNKS1BP1 139.35 0.00 10987.73 959.22 6.88 
ATF6 34.75 1121.22 5027.95 912.74 26.26 
IGHG1 29639.85 1540.79 4211.78 755.82 0.03 
DCAF15 46.40 849.52 10033.49 653.95 14.09 
LINC00514 49.58 0.00 2085.88 587.31 11.85 




Supplementary Table 9 – Yuhan011 unselected library NGS data: Panning was performed on an 
oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan011 using the antigen 
phage library from the same patient. Phage particles were sampled after amplification of selection round two 
and after elution of selection round three. Unselected library and selected samples were analysed via NGS. 















KRT17 38981.93 23845.59 0.94 
SPP1 24289.03 7757.36 2.83 
KRT5 16286.92 16677.48 2.83 
GAPDH 11102.94 11222.52 353.27 
HSPA1A 9545.94 0.00 1.43 
HSPA1A 9545.94 6508.33 0.00 
KRT6A 9325.96 6911.77 6.14 
ACTB 7673.30 3335.24 0.94 
ITGB4 4955.00 4136.38 3.78 
IGHG1 4901.87 1877.51 0.00 
FLNA 4363.99 2516.12 0.94 
IGKC 4323.74 2335.02 0.00 
PKM 3726.00 2276.18 0.47 
H3F3B 3679.00 1592.35 0.00 
MYH9 3553.95 1958.62 2.83 
IGHG4 3506.35 1797.10 0.00 
SFN 3471.00 350.02 0.00 
ALDH3A1 3401.00 3325.24 0.47 
LAMB3 3391.00 5573.54 0.47 





Supplementary Table 10 – Yuhan011 2nd amplification sample NGS data: Panning was performed on an 
oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan011 using the antigen 
phage library from the same patient. Phage particles were sampled after amplification of selection round two 
and after elution of selection round three. Unselected library and selected samples were analysed via NGS. 
Read counts across all samples for the twenty genes with the highest read counts in the amplified sample are 
shown. Enrichment factors are calculated by dividing the read count for a gene in the eluted sample by the 



















MMP9 309.98 413440.74 519102.57 1333.77 
MYC 428.00 72782.61 475374.10 170.05 
KRT17 38981.93 23845.59 0.94 0.61 
KRT5 16286.92 16677.48 2.83 1.02 
GAPDH 11102.94 11222.52 353.27 1.01 
SPP1 24289.03 7757.36 2.83 0.32 
KRT6A 9325.96 6911.77 6.14 0.74 
HSPA1A 9545.94 6508.33 0.00 0.68 
LAMB3 3391.00 5573.54 0.47 1.64 
ITGB4 4955.00 4136.38 3.78 0.83 
ASL 43.55 4074.49 0.00 93.56 
EEF1A1 2595.79 4045.24 0.00 1.56 
ACTB 7673.30 3335.24 0.94 0.43 
ALDH3A1 3401.00 3325.24 0.47 0.98 
ACTG1 2295.76 3270.10 0.00 1.42 
YBX1 205.97 2866.12 0.94 13.92 
MT-CO3 1677.92 2859.35 0.47 1.70 
LMNA 2742.00 2779.40 0.00 1.01 
TPT1 1610.15 2729.17 1.42 1.69 




Supplementary Table 11 – Yuhan011 3rd amplification sample NGS data: Panning was performed on an 
oligoclonal mixture of recombinant scFv-Fc antibodies derived from TIBC from Yuhan011 using the antigen 
phage library from the same patient. Phage particles were sampled after amplification of selection round two 
and after elution of selection round three. Unselected library and selected samples were analysed via NGS. 
Read counts across all samples for the twenty genes with the highest read counts in the 3rd elution sample are 
shown. Enrichment factors are calculated by dividing the read count for a gene in the eluted sample by the 


















MMP9 309.98 413440.74 519102.57 1674.63 
MYC 428.00 72782.61 475374.10 1110.69 
UBA7 11.00 922.75 3751.80 341.07 
GAPDH 11102.94 11222.52 353.27 0.03 
SLBP 38.00 343.94 345.71 9.10 
TRIP10 56.00 383.51 215.36 3.85 
COL1A1 1065.00 1654.76 170.49 0.16 
IGLV1-40 34.85 213.57 167.18 4.80 
CCDC149 14.00 156.75 146.88 10.49 
AHNAK 481.00 353.58 32.59 0.07 
CNST 20.00 421.04 25.50 1.28 
LGALS3 328.64 308.93 22.67 0.07 
TALDO1 591.00 647.29 19.36 0.03 
ACADM 25.00 57.32 15.11 0.60 
SLC2A1 550.00 1374.23 14.64 0.03 
PEAR1 6.00 62.40 11.33 1.89 
ZFP36L2 439.00 1512.72 8.03 0.02 
MLF2 198.00 1112.47 7.08 0.04 
IGHV3-65 1.00 2.44 6.61 6.61 







Supplementary Figure 1 – MSLN sequence alignment: amino acid sequences of MSLN fragments selected 
from after different pannings with anti-MSLN antibody SuW57-D11 were aligned using ClustalW. Sequences 
longer than position 85 in the alignment view were cropped to improve visibility. 
 
 
